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Key Points 
Question: Is first-trimester maternal antidepressant use related to offspring birth and/or 
neurodevelopmental problems? Findings: In this retrospect cohort study of 1,580,629 Swedish 
offspring using multiple statistical and methodical approaches to adjust for confounding, first-
trimester antidepressant exposure was significantly associated with preterm birth (OR = 1.3 in a 
sibling comparison analysis) but not with risk of being born small for gestational age or later 
autism spectrum disorder or attention-deficit/hyperactivity disorder. Meaning: After accounting 
for confounding factors, first-trimester antidepressant exposure, compared with no exposure, was 
associated with a small increased risk of preterm birth but no increased risk of small for 
gestational age, autism spectrum disorder, or attention-deficit/hyperactivity disorder. 
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Abstract 
Importance: Prenatal antidepressant exposure has been associated with adverse outcomes. 
Previous studies, however, may not have adequately accounted for confounding.  
Objective: To evaluate alternative hypotheses for associations between first-trimester 
antidepressant exposure and birth and neurodevelopmental problems.  
Design, Setting, and Participants: This retrospective cohort study included Swedish offspring 
born between 1996 and 2012 and followed through 2013 or censored by death or emigration. 
Analyses controlling for pregnancy, maternal, and paternal covariates, as well as sibling 
comparisons, timing of exposure comparisons, and paternal comparisons, were used to examine 
the associations.  
Exposures: Maternal self-reported first-trimester antidepressant use and first-trimester 
antidepressant dispensations.  
Main Outcomes and Measures: Preterm birth (< 37 gestational weeks), small for gestation age 
(birth weight < 2 SDs below the mean for gestational age), and first inpatient or outpatient 
clinical diagnosis of autism spectrum disorder and attention-deficit/hyperactivity disorder in 
offspring.  
Results: Among 1,580,629 offspring (mean gestational age 279 days; 48.6% female; 1.4% [n = 
22,544] with maternal first-trimester self-reported antidepressant use) born to 943,776 mothers 
(mean age at childbirth 30 years), 7.0% of exposed vs. 4.8% of unexposed offspring were 
preterm, 2.5% of exposed vs. 2.2% of unexposed were small for gestational age, 5.3% of 
exposed vs. 2.1% of unexposed were diagnosed with autism spectrum disorder by age 15, and 
12.6% of exposed vs. 5.5% of unexposed were diagnosed by attention-deficit/hyperactivity 
disorder by age 15. At the population level, first-trimester exposure was associated with all 
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outcomes, compared with unexposed offspring (preterm birth: OR = 1.5, 95% CI, [1.4, 1.6]; 
small for gestational age: OR = 1.2, 95% CI, [1.1, 1.3]; autism spectrum disorder: HR = 2.0, 95% 
CI, [1.8, 2.3]; attention-deficit/hyperactivity disorder: HR = 2.2, 95% CI, [2.0, 2.4]). However, in 
models that compared siblings while adjusting for pregnancy, maternal, and paternal traits, first-
trimester antidepressant exposure was associated with preterm birth (OR = 1.3, 95% CI [1.2, 
1.5]) but not with small for gestational age (OR = 1.0, 95% CI [0.8, 1.3]), autism spectrum 
disorder (HR = 0.8, 95% CI [0.6, 1.1]), or attention-deficit/hyperactivity disorder (HR = 1.0, 95% 
CI [0.8, 1.3]). Results from analyses assessing associations with maternal dispensations before 
pregnancy and paternal first-trimester dispensations were consistent with findings from the 
sibling comparisons.   
Conclusion and Relevance: Among offspring born in Sweden, after accounting for confounding 
factors, first-trimester antidepressant exposure, compared to no exposure, was associated with a 
small increased risk of preterm birth but no increased risk of small for gestational age, autism 
spectrum disorder, or attention-deficit/hyperactivity disorder.   
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 Given the increasing prevalence of antidepressant use among pregnant women,
1
 gaining 
knowledge on the safety of their use during pregnancy is a public health priority. Prenatal 
antidepressant exposure is associated with birth and neurodevelopmental problems, including 
shorter gestation,
2
 reduced fetal growth,
2
 autism spectrum disorder,
3-6
 and attention-
deficit/hyperactivity disorder.
7
 These associations may be due to causal mechanisms (e.g., 
dysfunctional serotonin signaling
8
). However, there are alternative explanations for the 
associations. Maternal depression and stress are associated with birth
9
 and neurodevelopmental
10
 
problems, suggesting that antidepressant associations could be attributable to confounding by 
indication for such treatment. Furthermore, autism spectrum disorder and attention-
deficit/hyperactivity disorder have strong genetic influences,
11
 and these influences partially 
overlap with genetic contributions to depression.
12,13
 Thus, genetic transmission of shared risk 
for neurodevelopmental problems and depression could explain the associations (i.e., passive 
gene-environmental correlation). Other factors, such as poor health practices during pregnancy, 
could also account for the associations.
14
 
Randomized clinical trials have not been able to test the safety of antidepressant use 
during pregnancy because pregnant women are typically excluded from these studies. Thus, 
researchers must use observational designs to rule out alternative explanations for the 
associations.
15
 The present study used four such designs to explore associations between first-
trimester antidepressant exposure (assessed via both maternal self-report and registered 
medication dispensations) and offspring birth and neurodevelopmental problem (i.e., preterm 
birth, small for gestational age, autism spectrum disorder, and attention-deficit/hyperactivity 
disorder. In addition to (1) statistical controls to adjust for measured pregnancy, maternal, and 
paternal characteristics, this study used (2) sibling comparisons to account for unmeasured 
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genetic and environmental factors that make siblings similar, (3) timing-of-exposure 
comparisons to account for selection factors related to maternal antidepressant treatment around 
the time of pregnancy, and (4) paternal comparisons to further account for familial confounding.   
Methods 
 The institutional review board at Indiana University and the Regional Ethical Review 
Board in Stockholm approved this study. By Swedish law informed consent was not necessary 
because the study used data available from national registers.  
Sample 
 We obtained a population-based dataset by linking information from the following 
Swedish registers: (1) the Multi-Generation Register, which included biological relationships for 
all individuals residing in Sweden since 1961, (2) the Prescribed Drug Register, which included 
prescription medication dispensation records since 2006, (3) the Medical Birth Register, which 
included information on 96-99% of births since 1973, (4) the National Patient Register, which 
included diagnoses from all hospital admissions since 1987 and specialist outpatient care since 
2001, (5) the National Crime Register, which included criminal convictions since 1973, and (6) 
the Education Register, which included highest level of completed formal education through 
2013.  
Measures 
 Antidepressant exposure. The main exposures evaluated were first-trimester exposure 
to (1) any antidepressants (medications with Anatomical Therapeutic Chemical Classification 
[ATC] codes beginning with N06A) and (2) Selective Serotonin Reuptake Inhibitors (SSRIs; 
medications with ATC codes beginning with N06AB). Exposure was defined according to two 
sources of information: (1) maternal self-reports (available for offspring born between 1996 and 
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2012) and (2) dispensation records (available for both parents of offspring born between 2006 
and 2012).  
Information on maternal self-reported medication use during the first trimester of 
pregnancy came from the Medical Birth Register, which contains information obtained from 
standardized interviews conducted by midwives at the first antenatal visit. Medication reported 
in these interviewers is presumed to represent first-trimester use because interviews typically 
occur between week 10 and 12 of pregnancy.  
 Information on medication use based on dispensation records came from the Prescribed 
Drug Register, which covers all medication dispensations and accompanying prescriptions made 
in Sweden since July 2005. The only medication use not covered by the register is medication 
administered while in hospital, purchased over the counter, or obtained on the black market. The 
Prescribed Drug Register was used to obtain information on maternal antidepressant 
dispensations that covered the periods before pregnancy and during the first trimester of 
pregnancy and paternal antidepressants that covered the period during the first trimester of 
pregnancy. First-trimester exposure was defined as having at least one dispensation between 90 
days before estimated conception and 90 days after estimated conception (see eFigure 1). The 
window included 90 days before conception because chronic disease medication is typically 
prescribed for at least 3-month periods in Sweden. Use before pregnancy only was defined as 
having at least one dispensation between 270 and 90 days before estimated conception and no 
dispensations during pregnancy or during the 180 days after delivery.  
 Main Outcomes. The birth outcomes were preterm birth (< 37 gestational weeks) and 
small for gestational age (birth weight < 2 SDs below the mean for gestational age). The 
neurodevelopmental outcomes were first diagnosis of autism spectrum disorder and attention-
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deficit/hyperactivity disorder, which were identified using inpatient and outpatient diagnoses 
made by specialists according to International Classification of Diseases, Ninth Revision (ICD-
9) and ICD-10 criteria. Previous research has validated these diagnoses in the Swedish 
registers.
16,17
 Participants were followed through 2013 or were censored because of death or 
emigration. More details about the registers and variables are available in previous 
publications.
e.g.,18,19
 
 Covariates. Pregnancy covariates included parity (categorized as first, second, third, or 
fourth or higher) and year of birth. Maternal and paternal covariates included country of birth 
(Sweden or outside Sweden), age at childbearing (categorized into six levels), highest level of 
completed education (categorized into seven levels), history of any criminal conviction, history 
of severe psychiatric problems (inpatient diagnosis of ICD-8, ICD-9, or ICD-10 schizophrenia, 
bipolar disorder, or other non-drug-induced psychoses), and history of any suicide attempts 
(definite or uncertain). History of criminal convictions is commonly used in Swedish register 
studies to index problems with behavior regulation.
e.g.,20,21
  
Analyses 
 We performed a complete-case analysis. We managed and analyzed data in SAS 9.4 and 
STATA 13.1 and calculated 95% confidence intervals based on two-sided hypothesis testing.  
 Descriptive statistics. We provided the distribution of covariates and outcomes in the 
whole sample and in the subsamples of exposed an unexposed offspring.  In addition, we 
provided the occurrence of the outcomes and covariates in differentially exposed and unexposed 
siblings. For the birth outcomes, we presented proportions and unadjusted risk differences. We 
presented Kaplan Meier estimates of the probability of the neurodevelopmental diagnoses 
because follow-up time was censored.  
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 Population-wide associations and within-family comparisons. Logistic regression was 
used to estimate the model-based associations for the two birth (i.e., binary response) outcomes. 
Cox proportional hazards regression (using calendar age in years as the timescale) was used to 
estimate the associations for the two neurodevelopmental outcomes to account for censored 
observations in the data. We examined the associations between antidepressant exposure and 
outcomes by estimating a sequence of three models with increasing degree of control for 
potential confounding factors. First, the baseline models assessed population-wide associations 
while only adjusting for pregnancy covariates (parity and year of birth). Second, the population-
wide associations were further adjusted for all maternal and paternal covariates. These 
population models used robust standard errors to account for clustering of individuals (i.e., 
siblings) within nuclear families bound by the same biological mother. Third, sibling comparison 
models compared exposure and outcome discordant offspring within families and included 
covariates that could vary among siblings born to the same mother. By design, these models 
accounted for all factors that made siblings similar (e.g., shared genetic and early environmental 
influences), as well as measured covariates that vary within families, thereby producing a 
stronger test of the associations than the adjusted population models.
22
 As recommended,
23
 we fit 
fixed-effects models using conditional logistic and stratified Cox regression to make purely 
within-family comparisons.  
 Comparisons of timing of maternal use and paternal use. To explore whether 
intrauterine exposure was specifically associated with outcomes over and above maternal 
depression treatment around the time of pregnancy, we compared associations for maternal first-
trimester antidepressant dispensations with associations for dispensations before pregnancy, 
while adjusting for measured pregnancy, maternal, and paternal covariates. We evaluated 
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whether these associations differed statistically using Wald χ2 tests. We also compared the fit of 
models that included separate parameters for before pregnancy dispensations and first-trimester 
dispensations to models that included one parameter for both dispensation windows. In addition, 
paternal first-trimester antidepressant dispensations were used as a negative control to further 
explore the role of familial confounding. We first assessed the association between maternal and 
paternal first-trimester dispensations. We then estimated associations between paternal first-
trimester antidepressant dispensations and the four outcomes while adjusting for the pregnancy 
covariates.  
 Sensitivity analyses. First, to evaluate the influence of exposure misclassification, we 
examined adjusted associations with five additional exposure definitions in the cohort with 
exposure information from both maternal self-reports and dispensations (i.e., the cohort born 
2006 to 2012). The four additional definitions included: (a) first-trimester exposure defined as 
use according to either self-reports or dispensation records, (b) first-trimester exposure defined 
as use according to both self-reports and dispensation records, (c) a narrower first-trimester 
dispensation window of 30 days before conception to 90 days after conception, and (d) at least 
two dispensations during the original first-trimester exposure window. Second, given that single-
offspring families cannot contribute to sibling-comparison analyses, we reassessed the 
population models in the subsample of offspring with siblings to evaluate the generalizability of 
sibling-comparison results. Third, to assess if exposure to other psychotropic medications 
confounded the associations, we restricted the analyses to offspring not exposed to other 
psychotropic medications. Fourth, given that prior to 2001 outpatient psychiatric diagnoses were 
not included in the National Patient Register, we conducted analyses on a subsample of offspring 
born after 2000 to assess whether left censoring of the neurodevelopmental outcomes biased the 
11 
 
findings. These analyses also enabled us to explore whether cohort effects influenced the results. 
Fifth, we estimated the associations with the neurodevelopmental outcomes in subsamples 
excluding offspring with diagnoses before age 2 to address concerns about the validity of early 
neurodevelopmental diagnoses. Sixth, because the main analyses focused on first-trimester 
exposure, we examined the association between dispensations during the second and/or third 
trimester and each outcome in the subsample of offspring whose mothers had a dispensation 
during the first trimester.   
Results 
 The target sample included 1,670,237 offspring born 1996-2012. Multiple births (48,979 
offspring), cases with missing father identifier (16,295), missing or invalid responses on 
covariates (20,118), and missing on the small for gestational age variable (4,216) were 
sequentially dropped. The final analytic cohort of 1,580,629 offspring (48.6% female) 
represented 95% of target singleton births and included 943,776 distinct mothers and 946,579 
distinct fathers. According to maternal self-reports, 22,544 (1.4%) of the offspring in the final 
cohort were exposed to any antidepressant during the first trimester, and of these, 82% (18,470) 
were exposed to SSRIs. 
 The timing of exposure and paternal comparisons were conducted on the subsample of 
708,450 offspring (born between 2006 and 2012) with dispensation-based exposure data. There 
were 26,477 (3.7%) offspring with first-trimester maternal antidepressant dispensations. Of 
these, 84% (22,125) had first-trimester maternal SSRI dispensations specifically. There were 
8,203 (1.2%) offspring who had mothers with antidepressant dispensations before pregnancy 
only. Of these, 81% (6,674) had mothers who were specifically dispensed SSRIs before 
pregnancy. There were 18,727 (2.6%) offspring who had fathers with first-trimester 
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antidepressant dispensations. Of these, 72% (13,521) had fathers with first-trimester SSRI 
dispensations specifically. 
 The same pattern of results was observed for associations with first-trimester exposure to 
any antidepressant as first-trimester exposure to SSRIs specifically. Therefore, results for 
exposure to any antidepressant are presented in the text and tables. The results for SSRIs can be 
found in the tables and online supplement. 
Descriptive Statistics Stratified By Maternal Self-reported Antidepressant Use 
In the whole sample, 7.0% of exposed and 4.8% of unexposed offspring were preterm 
(Table 1), which equates to 220 (95% CI [187, 254]) additional preterm birth cases per 10,000 
offspring. Approximately 2.5% of exposed and 2.2% of unexposed offspring were born small for 
gestational age, (risk difference = 35 additional cases per 10,000 offspring; 95% CI [14, 56]). 
Compared to unexposed offspring, exposed offspring also had a higher probability of the 
neurodevelopmental diagnoses (see Figure 1a and 1c for the Kaplan Meier estimates and 
confidence intervals). For example, by age 15, Kaplan Meier estimates indicated a cumulative 
risk of autism spectrum disorder of 5.3% for exposed and 2.1% for unexposed offspring. By age 
15, the cumulative risk of attention-deficit/hyperactivity disorder was 12.6% for exposed and 
5.5% for unexposed offspring. See eSupplement A for more descriptive information. 
Among differentially exposed siblings, 6.2% of exposed and 5.1% of unexposed siblings 
were born preterm. However, 1.9% of exposed and 2.0% of unexposed siblings were small for 
gestational age. See Figure 1b and 1d for the probabilities of the neurodevelopmental diagnoses 
among differentially exposed siblings through age 15. By age 15, the cumulative risk for autism 
spectrum disorder was 5.5% for exposed and 4.6% for unexposed siblings; the cumulative risk 
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for attention-deficit/hyperactivity disorder was 12.4% for exposed and 12.7% for unexposed 
siblings.  
Population-wide Associations and Sibling Comparisons 
In the baseline models (Table 2), maternal self-reported first-trimester antidepressant use 
was associated with preterm birth (OR = 1.5, 95% CI [1.4, 1.6]), small for gestational age 
(OR = 1.2, 95% CI [1.1, 1.3]), autism spectrum disorder (HR = 2.0, 95% CI [1.8, 2.3]), and 
attention-deficit/hyperactivity disorder (HR = 2.2, 95% CI [2.0, 2.4]). In the adjusted models, 
first-trimester exposure to antidepressants was also statistically significantly associated with all 
outcomes (preterm birth OR = 1.4, 95% CI [1.3, 1.4]; small for gestational age OR = 1.1, 95% CI 
[1.0, 1.2]; autism spectrum disorder HR = 1.6, 95% CI [1.5, 1.8]; attention-deficit/hyperactivity 
disorder HR = 1.6, 95% CI [1.5, 1.7]).  
In the sibling comparison models, first-trimester exposure was associated with preterm 
birth (OR = 1.3, 95% CI [1.2, 1.5], p < 0.0001). However, it was not associated with small for 
gestational age (OR = 1.0, 95% CI [0.8, 1.3]), autism spectrum disorder (HR = 0.8, 95% CI [0.6, 
1.1]), or attention-deficit/hyperactivity disorder (HR = 1.0, 95% CI [0.8, 1.3]). See eSupplement 
A for information on offspring who could contribute to sibling comparison analyses.  
Comparisons of Timing of Maternal Use and Paternal Use 
 Dispensation data was used in timing of exposure and paternal comparisons (see 
eSupplement B for more information). For preterm birth, the association with maternal 
dispensations before pregnancy but not during or after pregnancy (OR = 1.2, 95% CI [1.1, 1.3]; 
Table 3) was statistically significantly weaker than the association with first-trimester maternal 
dispensations (OR = 1.4, 95% CI [1.3, 1.5]). For all other outcomes, the associations with 
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maternal dispensations before but not during or after pregnancy did not statistically significantly 
differ from the associations with first-trimester maternal dispensations. 
 Paternal first-trimester antidepressant dispensations were associated with maternal first-
trimester antidepressant dispensations (OR = 3.4, 95% CI [3.3, 3.6]). Paternal first-trimester 
antidepressant dispensations (Table 4) had very modest associations with preterm birth (OR = 
1.1, 95% CI [1.1, 1.2]) and small for gestational age (OR = 1.1, 95% CI [1.0, 1.2]), with the latter 
not being statistically significant. Paternal dispensations during pregnancy were associated with 
autism spectrum disorder (HR = 1.3, 95% CI [1.1, 1.6]), and attention-deficit/hyperactivity 
disorder (HR = 1.7, 95% CI [1.4, 2.2]). 
Sensitivity Analyses 
 Sensitivity analyses showed a consistent pattern of results across analyses using stricter 
criteria for exposure and narrower exposure windows, suggesting that exposure misclassification 
was not responsible for the pattern of findings (eSupplement C).  Results from population 
models conducted on a subsample that excluded offspring who did not have siblings also were 
essentially identical to the main results (eSupplement D). These results provide support for the 
generalizability of sibling comparison results. Sensitivity analyses also suggested that 
confounding by exposure to other psychotropic medications (eSupplement E); left censoring of 
the neurodevelopmental outcomes and cohort effects (eSupplement F); and measurement error of 
the neurodevelopmental outcomes (eSupplement G) had very little influence on the results. In 
addition, among offspring whose mothers had a dispensation during the first trimester, a 
dispensation during the second or third trimester was associated with increased risk of the 
pregnancy outcomes, though the associations with the neurodevelopmental diagnoses were not 
statistically significant (eSupplement H). 
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Discussion 
  The present study found that, after accounting for measured pregnancy, maternal, and 
paternal traits, as well as all (unmeasured) stable familial characteristics shared by siblings, 
maternal antidepressant use during the first trimester of pregnancy, compared to no exposure, 
was associated with a small increased risk of preterm birth but no increased risk of small for 
gestational age, autism spectrum disorder, or attention-deficit/hyperactivity disorder. That is, 
unexposed siblings were at equal risk for small for gestational age, autism spectrum disorder, and 
attention-deficit/hyperactivity disorder as their exposed siblings. These results are consistent 
with the hypothesis that genetic and/or familial environmental factors account for the population-
wide associations between first-trimester antidepressant exposure and these outcomes. Moreover, 
results from analyses examining timing of exposure were consistent with the interpretation of the 
sibling-comparison findings. Specifically, the strength of the associations between antidepressant 
dispensations before pregnancy and small for gestational age, autism spectrum disorder, and 
attention-deficit/hyperactivity disorder did not statistically significantly differ from that of 
associations for first-trimester antidepressant dispensations, suggesting that the underlying 
condition, rather than exposure to antidepressants during the first trimester, explained the 
associations. Paternal first-trimester antidepressant dispensations were also associated with the 
neurodevelopmental disorders. Because paternal antidepressant use during the first trimester is 
unlikely to contribute to intrauterine exposure, these findings provide further support that 
associations between first-trimester antidepressant exposure and offspring neurodevelopmental 
problems may, at least partially, be explained by familial confounding. 
 The results also showed that, across multiple designs that account for familial 
confounding factors, first-trimester antidepressant exposure was associated with a slightly 
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elevated risk of preterm birth. Although these results may be consistent with the hypothesis that 
prenatal antidepressant exposure could lead to a small increased risk of preterm birth, other 
possible explanations for the findings need to be considered. Most important, the potential role of 
confounding by maternal depression should be noted because both the existence and severity of 
depression symptoms in the mother could potentially influence the risk of preterm birth.
24
  
 The results of the population-wide models were consistent with numerous observational 
studies that have demonstrated associations between prenatal antidepressant exposure and birth 
and neurodevelopmental problems.
2-7
 The results of the sibling comparisons were also consistent 
with the limited previous sibling-comparisons studies that have examined associations between 
prenatal antidepressant exposure and birth and neurodevelopmental problems. A sibling 
comparison study using dispensation data from the Swedish registers found a statistically 
significant associations between prenatal antidepressant dispensations and shorter gestation.
25
 
Another sibling comparison reported that prenatal antidepressant exposure was not associated 
with autism spectrum disorder,
26
 although confidence intervals were too wide to draw strong 
conclusions.  
 The current study had several strengths. First, the study analyzed a large, population-
based sample, which provided statistical power to examine rare-yet-serious outcomes. Second, 
the conclusions were based on converging evidence from multiple research designs that 
accounted for both measured and unmeasured confounding factors. Third, first-trimester 
antidepressant use was indexed by both maternal self-report and dispensations. Fourth, the study 
included four outcomes, two pregnancy-related and two neurodevelopmental problems, all of 
which are associated with significant morbidity and mortality. Fifth, sensitivity analyses 
suggested that misclassification of antidepressant use, several assumptions of sibling-comparison 
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analyses, confounding by other psychotropic medications, and misclassification of the 
neurodevelopmental problems were unlikely to influence the overall conclusions.    
 The findings from the present study should be considered in light of several limitations. 
First, and most important, observational designs such as these cannot fully rule out all sources of 
confounding. In particular, like other register-based approaches,
26
 this study could not 
comprehensively assess maternal depression or its severity,
27
 nor could it compare different 
antidepressant treatment regimes. Thus, associations could have been influenced by confounding 
by antidepressant indication. In order to address this limitation, the study used multiple designs, 
each of which could help rule out some but not all sources of confounding, to provide 
complementary evidence. For example, sibling comparisons ruled out all stable confounders 
(e.g., chronic maternal depression), but that design may not have been able to account for 
confounding from maternal depression that varied across pregnancies.
28
 Thus, the within-family 
associations with preterm birth may plausibly be driven by unmeasured time-varying maternal 
depression rather than by antidepressant use.
29
    
 Second, this study focused on first-trimester exposure. Whereas one recent study found 
an association between antidepressant dispensations late—but not early—in pregnancy and 
autism spectrum disorder,
3
 there has been considerable debate regarding the role of timing.
30-32
 
In fact, several studies have found stronger associations with first-trimester antidepressant use 
than with use later in pregnancy.
4,6
 Supplemental analyses indicated that among offspring whose 
mothers had a dispensation during the first trimester, a dispensation during the second or third 
trimester was associated with greater risk of offspring being born preterm and small for 
gestational age. These associations could be due to intrauterine exposure to antidepressants later 
in pregnancy, increased severity of depression (i.e., confounding by indication), or other 
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unmeasured confounding. Future studies are, therefore, needed to explicitly examine whether 
timing of exposure moderates the preterm birth association or whether exposure later in 
pregnancy is more strongly associated with other outcomes.  
Third, the vast majority of antidepressant exposure (82% according to maternal reports) 
was to SSRIs. Future research should explore class- and drug-specific associations. Fourth, 
analyses were conducted on a Swedish sample, and it is not known if results would generalize to 
other countries. Although the population-wide associations in the present study were 
commensurate with those from other countries, future research should use designs that help 
account for unmeasured confounders to explore associations with prenatal antidepressant 
exposure in the United States and elsewhere. Fifth, sibling comparisons require large samples to 
have adequate statistical power.
33
 Although the large Swedish sample ensured fairly precise 
parameter estimates in sibling comparisons, small effects of antidepressant exposure cannot be 
ruled out. However, their magnitudes, particularly for the neurodevelopmental outcomes, would 
be much smaller than those suggested by population-wide associations.  
Conclusion 
 Among offspring born in Sweden, after accounting for confounding factors, first-
trimester exposure to antidepressants, compared to no exposure, was associated with a small 
increased risk of preterm birth but no increased risk of small for gestational age, autism spectrum 
disorder, or attention-deficit/hyperactivity disorder.   
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Figure 1. Risk of Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder by Maternal Self-
reported First-trimester Exposure. The figure shows Kaplan-Meier estimates of cumulative risk (i.e., proportion 
diagnosed with) the neurodevelopmental outcomes (y-axis) by age (x-axis) among offspring with and without 
maternal self-reported first-trimester antidepressant exposure. The blue line shows exposed offspring. The black line 
shows unexposed offspring. Shaded areas around the blue and black lines are pointwise 95% confidence intervals. 
Top panels (A and B) show risk for autism spectrum disorder. Bottom panels (C and D) show risk for attention-
deficit/hyperactivity disorder. Left panels (A and C) include the full cohort. Right panels (B and D) include siblings 
discordant for first-trimester antidepressant exposure. The median and interquartile range (IQR) follow-up time in 
the study (i.e., age since birth in years) were estimated separately for each exposure group. The median follow-up 
for autism spectrum disorder in the full cohort was 8.71 y [IQR: (4.69, 13.19)] for the unexposed group, and 5.82 y 
[IQR: (3.32, 9.08)] for the exposed group.  The median follow-up for autism spectrum disorder in the sample of 
discordant siblings was 9.24 y [IQR: (5.54, 12.96)] for the unexposed group, and 6.27 y [IQR: (3.77, 9.02)] for the 
exposed group. The median follow-up for attention-deficit/hyperactivity disorder in the full cohort was 8.54 y [IQR: 
(4.54, 13.54)] for the unexposed group, and 5.54 y [IQR: (3.54, 9.54)] for the exposed group. The median follow-up 
for attention-deficit/hyperactivity disorder in the sample of discordant siblings was 9.54 y [IQR: (5.54, 13.54)] for 
the unexposed group, and 6.54 y [IQR: (3.54, 9.54)] for the exposed group. 
  
26 
 
Table 1. Descriptive statistics in the whole sample and stratified by maternal self-reported first-trimester use 
of any antidepressant  
  
Whole sample 
(n=1,580,629) 
Exposed offspring 
(n=22,544) 
Unexposed offspring 
(n=1,558,085) 
 
No. (%) No. (%) No. (%) 
Offspring outcomes 
   
  Preterm birth 76061 (4.81) 1574 (6.98) 74487 (4.78) 
  Small for gestational age 34728 (2.20) 573 (2.54) 34155 (2.19) 
  Autism spectrum disorder
a
 14617 (2.16) 299 (5.28) 14318(2.14) 
  Attention-deficit/hyperactivity disorder
a
 32924 (5.51) 613 (12.63) 32311(5.46) 
 
Pregnancy covariates   
 
  First born 693070 (43.85) 10467 (46.43) 682603 (43.81) 
  Second born 585619 (37.05) 6891 (30.57) 578728 (37.14) 
  Third born 213382 (13.50) 3463 (15.36) 209919 (13.47) 
  Fourth born or higher 88558 (5.60) 1723 (7.64) 86835 (5.57) 
  Born 1996 to 1999
b
 333791 (21.12) 1649 (7.31) 332142 (21.32) 
  Born 2000 to 2003
b
 349143 (22.09) 3004 (13.33) 346139 (22.22) 
  Born 2004 to 2007
b
 386511 (24.45) 6349 (28.16) 380162 (24.40) 
  Born 2008 to 2012
b
 511184 (32.34) 11542 (51.20) 499642 (32.07) 
 
Maternal covariates    
  Age at birth 
  
 
      < 20 years 25637 (1.62) 327 (1.45) 25310 (1.62) 
      20 to 24 years 210552 (13.32) 2636 (11.69) 207916 (13.34) 
      25 to 29 years 495050 (31.32) 6124 (27.16) 488926 (31.38) 
      30 to 34 years 544746 (34.46) 7599 (33.71) 537147 (34.47) 
      35 to 39 years 254771 (16.12) 4730 (20.98) 250041 (16.05) 
      > 40 years 49873 (3.16) 1128 (5.00) 48745 (3.13) 
  Education 
  
 
     Primary and lower secondary, < 9 years 33648 (2.13) 180 (0.80) 33468 (2.15) 
     Primary and lower secondary, 9 years 107953 (6.83) 2684 (11.91) 105269 (6.76) 
     Upper secondary, 1-2 years 246415 (15.59) 3852 (17.09) 242563 (15.57) 
     Upper secondary, 3 years 414949 (26.25) 6053 (26.85) 408896 (26.24) 
     Post-secondary, < 3 years 224706 (14.22) 3012 (13.36) 221694 (14.23) 
     Post-secondary, > 3 years 533710 (33.77) 6585 (29.21) 527125 (33.83) 
     Postgraduate  19248 (1.22) 178 (0.79) 19070 (1.22) 
  Nationality (Swedish) 1281142 (81.05) 20361 (90.32) 1260781 (80.92) 
  Criminal convictions (any) 173631 (10.98) 3973 (17.62) 169658 (10.89) 
  Severe psychiatric problem
c
 16736 (1.06) 1734 (7.69) 15002 (0.96) 
  Suicide attempt (definite or uncertain) 66655 (4.22) 3251 (14.42) 63404 (4.07) 
 
Paternal covariates   
 
  Age at birth 
  
 
      < 20 years 7789 (0.49) 134 (0.59) 7655 (0.49) 
      20 to 24 years 100339 (6.35) 1543 (6.84) 98796 (6.34) 
      25 to 29 years 364992 (23.09) 4815 (21.36) 360177 (23.12) 
      30 to 34 years 547663 (34.65) 7118 (31.57) 540545 (34.69) 
      35 to 39 years 355300 (22.48) 5380 (23.86) 349920 (22.46) 
      > 40 years 204546 (12.94) 3554 (15.76) 200992 (12.90) 
  Education    
     Primary and lower secondary, < 9 years 29369 (1.86) 257 (1.14) 29112 (1.87) 
     Primary and lower secondary, 9 years 153577 (9.72) 2672 (11.85) 150905 (9.69) 
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     Upper secondary, 1-2 years 403919 (25.55) 5647 (25.05) 398272 (25.56) 
     Upper secondary, 3 years 381746 (24.15) 6271 (27.82) 375475 (24.10) 
     Post-secondary, < 3 years 233560 (14.78) 2930 (13.00) 230630 (14.80) 
     Post-secondary, > 3 years 348397 (22.04) 4404 (19.54) 343993 (22.08) 
     Postgraduate  30061 (1.90) 363 (1.61) 29698 (1.91) 
  Nationality (Swedish) 1273973 (80.60) 19699 (87.38) 1254274 (80.50) 
  Criminal convictions (any) 582002 (36.82) 9313 (41.31) 572689 (36.76) 
  Severe psychiatric problem
c
 10373 (0.66) 321 (1.42) 10052 (0.65) 
  Suicide attempt (definite or uncertain) 64879 (4.10) 1364 (6.05) 63515 (4.08) 
All percentages are based on the number of offspring. 
a
Age 15 Kaplan Meier estimates.
 b
Year of birth is presented in 
bins in Table 1 but was not binned when used as a covariate in models. 
c
Severe psychiatric problem was defined as 
an inpatient or outpatient diagnosis of schizophrenia, bipolar disorder, or other non-drug induced psychosis. 
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Table 2. Baseline, adjusted, and sibling comparison associations between maternal self-reported first-
trimester use and birth and neurodevelopmental outcomes 
 Baseline Model Adjusted Model Sibling Comparison 
Any antidepressant  
 OR 95% CI OR 95% CI OR. 95% CI 
Preterm birth 1.47 1.40-1.55 1.35 1.28-1.42 1.34 1.18-1.52 
Small for gestational age 1.15 1.06-1.25 1.12 1.03-1.22 1.01 0.81-1.25 
 
     
 
 HR 95% CI HR 95% CI HR 95% CI 
Autism spectrum disorder 2.02 1.80-2.26 1.64 1.46-1.83 0.83 0.62-1.13 
Attention-deficit/hyperactivity disorder 2.21 2.04-2.39 1.58 1.46-1.71 0.99 0.79-1.25 
SSRIs  
 OR 95% CI OR 95% CI OR. 95% CI 
Preterm birth 1.38 1.30-1.46 1.27 1.20-1.35 1.33 1.16-1.53 
Small for gestational age 1.11 1.01-1.21 1.09 0.99-1.20 0.88 0.70-1.12 
       
 HR 95% CI HR 95% CI HR 95% CI 
Autism spectrum disorder 2.04 1.80-2.32 1.66 1.46-1.89 0.81 0.58-1.14 
Attention-deficit/hyperactivity disorder 2.25 2.06-2.46 1.60 1.47-1.75 0.94 0.73-1.22 
OR = odds ratio. HR = hazard ratio. CI = confidence interval. Baseline and adjusted models were fit in a sample of 
1,580,629 offspring. See eSupplement A for information about offspring who could be informative in sibling 
comparisons. Baseline models controlled for parity and year of birth. Adjusted models controlled parity and year of 
birth and maternal and paternal country of birth, age at childbearing, highest level of completed education, history of 
any criminal convictions, history of severe psychiatric problems, and history of any suicide attempts. Sibling 
comparisons controlled for parity and year of birth, paternal country of birth, age at childbearing, highest level of 
completed education, history of any criminal convictions, history of severe psychiatric problems, and history of any 
suicide attempts, and maternal age at childbearing. 
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Table 3. Adjusted associations between maternal antidepressant dispensations before pregnancy and during 
the first trimester of pregnancy and birth and neurodevelopmental outcomes 
 
Before pregnancy 1
st
 trimester 
Any antidepressant     
 OR 95% CI OR 95% CI 
Preterm birth 1.17 1.07-1.28 1.40 1.33-1.47 
Small for gestational age 1.07 0.93-1.24 1.12 1.03-1.21 
 
    
 HR 95% CI HR 95% CI 
Autism spectrum disorder 1.40 1.02-1.93 1.75 1.49-2.07 
Attention-deficit/hyperactivity disorder 2.09 1.53-2.86 1.85 1.55-2.20 
SSRIs   
  
 OR 95% CI OR 95% CI 
Preterm birth 1.13 1.02-1.25 1.37 1.30-1.45 
Small for gestational age 1.09 0.94-1.28 1.13 1.03-1.23 
     
 HR 95% CI HR 95% CI 
Autism spectrum disorder 1.49 1.06-2.10 1.72 1.43-2.06 
Attention-deficit/hyperactivity disorder 1.93 1.35-2.74 1.81 1.50-2.19 
OR = odds ratio. HR = hazard ratio. CI = confidence interval. All models were fit in a sample of 708,450 offspring. 
Models controlled parity and year of birth and maternal and paternal country of birth, age at childbearing, highest 
level of completed education, history of any criminal convictions, history of severe psychiatric problems, and 
history of any suicide attempts. 
 
 
  
30 
 
Table 4. Baseline associations between paternal first-trimester antidepressant dispensations and birth and 
neurodevelopmental outcomes 
 
OR = odds ratio. HR = hazard ratio. CI = confidence interval. All models were fit in a sample of 708,450 offspring. 
Models controlled for parity and year of birth. Analyses compared offspring of fathers with first trimester 
antidepressant dispensations to offspring of fathers who were not dispensed antidepressants before pregnancy, 
during the second and third trimester of pregnancy, and after pregnancy (eFigure 1 shows dispensation windows). 
 Any Antidepressant SSRIs 
 OR 95% CI OR 95% CI 
Preterm birth 1.13 1.05-1.20 1.13 1.05-1.22 
Small for gestational age 1.06 0.96-1.17 1.00 0.89-1.13 
 
    
 HR 95% CI HR 95% CI 
Autism spectrum disorder 1.31 1.05-1.62 1.27 0.98-1.65 
Attention-deficit/hyperactivity disorder 1.73 1.38-2.17 1.71 1.31-2.23 
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eSupplement A: 
Descriptive Statistics Based on Maternal Self-reported Antidepressant Use 
 
In the main paper, we presented the distribution of covariates and outcomes stratified by maternal self-reported use 
of any antidepressant (Table 1). We have also provided the distribution of outcomes and covariates stratified by 
maternal self-reported use of any antidepressant in a subsample of differentially exposed siblings (eTable 1), as well 
as the distribution of outcomes and covariates stratified by maternal self-reported use of SSRIs specifically in all 
offspring in the sample and in a subsample of differentially exposed siblings (eTables 2 and 3, respectively). 
Because families in which all siblings are concordant on the outcomes cannot contribute to sibling comparison 
analyses, we have also provided information about subsamples of offspring from families with outcome-discordant 
siblings (eTable 4).  
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eTable 1. Descriptive statistics stratified by maternal self-reported first-trimester 
use of any antidepressant in a subsample of differentially exposed siblings 
  
Exposed offspring 
(n=10,975) 
Unexposed offspring 
(n=13,994) 
 
No. (%) No. (%) 
Offspring outcomes 
  
  Preterm birth 685 (6.24) 710 (5.07) 
  Small for gestational age 205 (1.87) 277 (1.98) 
  Autism spectrum disorder
a
 136 (5.52) 274 (4.55) 
  Attention-deficit/hyperactivity disorder
a
 280 (12.38) 699 (12.73) 
 
Pregnancy covariates 
  
  First born 2942 (26.81) 5803 (41.47) 
  Second born 4279 (38.99) 5346 (38.20) 
  Third born 2506 (22.83) 1803 (12.88) 
  Fourth born or higher 1248 (11.37) 1042 (7.45) 
  Born 1996 to 1999
b
 534 (4.87) 2648 (18.92) 
  Born 2000 to 2003
b
 1592 (14.51) 3653 (26.10) 
  Born 2004 to 2007
b
 3658 (33.33) 3882 (27.74) 
  Born 2008 to 2012
b
 5191 (47.30) 3811 (27.23) 
 
Maternal covariates 
  
  Age at birth   
      < 20 years 111 (1.01) 509 (3.64) 
      20 to 24 years 1203 (10.96) 3158 (22.57) 
      25 to 29 years 3061 (27.89) 4720 (33.73) 
      30 to 34 years 3853 (35.11) 3800 (27.15) 
      35 to 39 years 2290 (20.87) 1543 (11.03) 
      > 40 years 457 (4.16) 264 (1.89) 
  Education   
     Primary and lower secondary, < 9 years 99 (0.90) 141 (1.01) 
     Primary and lower secondary, 9 years 1375 (12.53) 1892 (13.52) 
     Upper secondary, 1-2 years 1951 (17.78) 2607 (18.63) 
     Upper secondary, 3 years 3022 (27.54) 3850 (27.51) 
     Post-secondary, < 3 years 1363 (12.42) 1670 (11.93) 
     Post-secondary, > 3 years 3077 (28.04) 3737 (26.70) 
     Postgraduate  88 (0.80) 97 (0.69) 
  Nationality (Swedish) 9856 (89.80) 12469 (89.10) 
  Criminal convictions (any) 2007 (18.29) 2722 (19.45) 
  Severe psychiatric problem
c
 812 (7.40) 991 (7.08) 
  Suicide attempt (definite or uncertain) 1552 (14.14) 2018 (14.42) 
 
Paternal covariates 
  
  Age at birth   
      < 20 years 50 (0.46) 191 (1.36) 
      20 to 24 years 706 (6.43) 1760 (12.58) 
      25 to 29 years 2358 (21.49) 4192 (29.96) 
      30 to 34 years 3571 (32.54) 4241 (30.31) 
      35 to 39 years 2666 (24.29) 2374 (16.96) 
      > 40 years 1624 (14.80) 1236 (8.83) 
  Education   
     Primary and lower secondary, < 9 years 137 (1.25) 180 (1.29) 
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Exposed offspring 
(n=10,975) 
Unexposed offspring 
(n=13,994) 
 No. (%) No. (%) 
     Primary and lower secondary, 9 years 1290 (11.75) 1769 (12.64) 
     Upper secondary, 1-2 years 2810 (25.60) 3748 (26.78) 
     Upper secondary, 3 years 3076 (28.03) 3872 (27.67) 
     Post-secondary, < 3 years 1422 (12.96) 1788 (12.78) 
     Post-secondary, > 3 years 2061 (18.78) 2420 (17.29) 
     Postgraduate  179 (1.63) 217 (1.55) 
  Nationality (Swedish) 9533 (86.86) 12023 (85.92) 
  Criminal convictions (any) 4603 (41.94) 6206 (44.35) 
  Severe psychiatric problem
c
 152 (1.38) 175 (1.25) 
  Suicide attempt (definite or uncertain) 621 (5.66) 802 (5.73) 
All percentages are based on the number of offspring. 
a
Age 15 Kaplan Meier estimates.
 b
Year of birth is presented in bins in eTable 
1 but was not binned when used as a covariate in models. 
c
Severe psychiatric problem was defined as an inpatient or outpatient 
diagnosis of schizophrenia, bipolar disorder, or other non-drug induced psychosis.
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eTable 2. Descriptive statistics stratified by maternal self-reported first-trimester 
SSRI use  
  
Exposed offspring 
(n=18,470) 
Unexposed offspring 
(n=1,562,159) 
 
No. (%) No. (%) 
Offspring outcomes   
  Preterm birth 1214 (6.57) 74847 (4.79) 
  Small for gestational age 453 (2.45) 34275 (2.19) 
  Autism spectrum disorder
a
 236 (5.21) 14381 (2.14) 
  Attention-deficit/hyperactivity disorder
a
 476 (13.29) 32448 (5.47) 
 
Pregnancy covariates 
 
 
  First born 8658 (46.88) 684412 (43.81) 
  Second born 5717 (30.95) 579902 (37.12) 
  Third born 2777 (15.04) 210605 (13.48) 
  Fourth born or higher 1318 (7.14) 87240 (5.58) 
  Born 1996 to 1999
b
 1063 (5.76) 332728 (21.30) 
  Born 2000 to 2003
b
 2340 (12.67) 346803 (22.20) 
  Born 2004 to 2007
b
 5230 (28.32) 381281 (24.41) 
  Born 2008 to 2012
b
 9837 (53.26) 501347 (32.09) 
 
Maternal covariates 
 
 
  Age at birth   
      < 20 years 290 (1.57) 25347 (1.62) 
      20 to 24 years 2224 (12.04) 208328 (13.34) 
      25 to 29 years 5123 (27.74) 489927 (31.36) 
      30 to 34 years 6146 (33.28) 538600 (34.48) 
      35 to 39 years 3794 (20.54) 250977 (16.07) 
      > 40 years 893 (4.83) 48980 (3.14) 
  Education   
     Primary and lower secondary, < 9 years 133 (0.72) 33515 (2.15) 
     Primary and lower secondary, 9 years 2115 (11.45) 105838 (6.78) 
     Upper secondary, 1-2 years 3009 (16.29) 243406 (15.58) 
     Upper secondary, 3 years 5043 (27.30) 409906 (26.24) 
     Post-secondary, < 3 years 2450 (13.26) 222256 (14.23) 
     Post-secondary, > 3 years 5588 (30.25) 528122 (33.81) 
     Postgraduate  132 (0.71) 19116 (1.22) 
  Nationality (Swedish) 16719 (90.52) 1264423 (80.94) 
  Criminal convictions (any) 3158 (17.10) 170473 (10.91) 
  Severe psychiatric problem
c
 1350 (7.31) 15386 (0.98) 
  Suicide attempt (definite or uncertain) 2530 (13.70) 64125 (4.10) 
 
Paternal covariates 
 
 
  Age at birth   
      < 20 years 116 (0.63) 7673 (0.49) 
      20 to 24 years 1287 (6.97) 99052 (6.34) 
      25 to 29 years 3973 (21.51) 361019 (23.11) 
      30 to 34 years 5890 (31.89) 541773 (34.68) 
      35 to 39 years 4371 (23.67) 350929 (22.46) 
      > 40 years 2833 (15.34) 201713 (12.91) 
  Education   
     Primary and lower secondary, < 9 years 194 (1.05) 29175 (1.87) 
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Exposed offspring 
(n=18,470) 
Unexposed offspring 
(n=1,562,159) 
 No. (%) No. (%) 
     Primary and lower secondary, 9 years 2141 (11.59) 151436 (9.69) 
     Upper secondary, 1-2 years 4460 (24.15) 399459 (25.57) 
     Upper secondary, 3 years 5261 (28.48) 376485 (24.10) 
     Post-secondary, < 3 years 2408 (13.04) 231152 (14.80) 
     Post-secondary, > 3 years 3697 (20.02) 344700 (22.07) 
     Postgraduate  309 (1.67) 29752 (1.90) 
  Nationality (Swedish) 16195 (87.68) 1257778 (80.52) 
  Criminal convictions (any) 7538 (40.81) 574464 (36.77) 
  Severe psychiatric problem
c
 247 (1.34) 10126 (0.65) 
  Suicide attempt (definite or uncertain) 1082 (5.86) 63797 (4.08) 
All percentages are based on the number of offspring. 
a
Age 15 Kaplan Meier estimates.
 b
Year of birth is presented in bins in eTable 
2 but was not binned when used as a covariate in models. 
c
Severe psychiatric problem was defined as an inpatient or outpatient 
diagnosis of schizophrenia, bipolar disorder, or other non-drug induced psychosis. 
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eTable 3. Descriptive statistics stratified by maternal self-reported first-trimester 
use of SSRIs in a subsample of differentially exposed siblings 
  
Exposed offspring 
(n=9,063) 
Unexposed offspring 
(n=15,906) 
 
No. (%) No. (%) 
Offspring outcomes   
  Preterm birth 544 (6.00) 851 (5.35) 
  Small for gestational age 162 (1.79) 320 (2.01) 
  Autism spectrum disorder
a
 108 (5.59) 229 (4.64) 
  Attention-deficit/hyperactivity disorder
a
 229 (13.61) 585 (13.00) 
 
Pregnancy covariates 
 
 
  First born 2377 (26.23) 6368 (40.04) 
  Second born 3639 (40.15) 5986 (37.63) 
  Third born 2072 (22.86) 2237 (14.06) 
  Fourth born or higher 975 (10.76) 1315 (8.27) 
  Born 1996 to 1999
b
 369 (4.07) 2813 (17.69) 
  Born 2000 to 2003
b
 1256 (13.86) 3989 (25.08) 
  Born 2004 to 2007
b
 3027 (33.40) 4513 (28.37) 
  Born 2008 to 2012
b
 4411 (48.67) 4591 (28.86) 
 
Maternal covariates 
 
 
  Age at birth   
      < 20 years 96 (1.06) 524 (3.29) 
      20 to 24 years 1003 (11.07) 3358 (21.11) 
      25 to 29 years 2554 (28.18) 5227 (32.86) 
      30 to 34 years 3146 (34.71) 4507 (28.34) 
      35 to 39 years 1888 (20.83) 1945 (12.23) 
      > 40 years 376 (4.15) 345 (2.17) 
  Education   
     Primary and lower secondary, < 9 years 83 (0.92) 157 (0.99) 
     Primary and lower secondary, 9 years 1075 (11.86) 2192 (13.78) 
     Upper secondary, 1-2 years 1555 (17.16) 3003 (18.88) 
     Upper secondary, 3 years 2548 (28.11) 4324 (27.18) 
     Post-secondary, < 3 years 1118 (12.34) 1915 (12.04) 
     Post-secondary, > 3 years 2614 (28.84) 4200 (26.41) 
     Postgraduate  70 (0.77) 115 (0.72) 
  Nationality (Swedish) 8157 (90.00) 14168 (89.07) 
  Criminal convictions (any) 1607 (17.73) 3122 (19.63) 
  Severe psychiatric problem
c
 630 (6.95) 1173 (7.37) 
  Suicide attempt (definite or uncertain) 1203 (13.27) 2367 (14.88) 
 
Paternal covariates 
 
 
  Age at birth   
      < 20 years 42 (0.46) 199 (1.25) 
      20 to 24 years 580 (6.40) 1886 (11.86) 
      25 to 29 years 1933 (21.33) 4617 (29.03) 
      30 to 34 years 2989 (32.98) 4823 (30.32) 
      35 to 39 years 2189 (24.15) 2851 (17.92) 
      > 40 years 1330 (14.68) 1530 (9.62) 
  Education   
     Primary and lower secondary, < 9 years 108 (1.19) 209 (1.31) 
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Exposed offspring 
(n=9,063) 
Unexposed offspring 
(n=15,906) 
 No. (%) No. (%) 
     Primary and lower secondary, 9 years 1054 (11.63) 2005 (12.61) 
     Upper secondary, 1-2 years 2283 (25.19) 4275 (26.88) 
     Upper secondary, 3 years 2557 (28.21) 4391 (27.61) 
     Post-secondary, < 3 years 1180 (13.02) 2030 (12.76) 
     Post-secondary, > 3 years 1727 (19.06) 2754 (17.31) 
     Postgraduate  154 (1.70) 242 (1.52) 
  Nationality (Swedish) 7898 (87.15) 13658 (85.87) 
  Criminal convictions (any) 3771 (41.61) 7038 (44.25) 
  Severe psychiatric problem
c
 122 (1.35) 205 (1.29) 
  Suicide attempt (definite or uncertain) 499 (5.51) 924 (5.81) 
All percentages are based on the number of offspring. 
a
Age 15 Kaplan Meier estimates.
 b
Year of birth is presented in bins in eTable 
3 but was not binned when used as a covariate in models. 
c
Severe psychiatric problem was defined as an inpatient or outpatient 
diagnosis of schizophrenia, bipolar disorder, or other non-drug induced psychosis. 
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eTable 4. Information on families with outcome discordant siblings in the cohort born 1996 to 2012  
 
Number of distinct outcome 
discordant siblings 
Number of distinct 
mothers with outcome 
discordant offspring 
Number of siblings with 
outcomes 
Preterm birth 96866 40416 42557 
Small for gestational age 45155 18926 19581 
Autism spectrum disorder 24969 10105 10371 
Attention-deficit/hyperactivity disorder 55526 22301 23522 
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eSupplement B: 
Descriptive Statistics and Analyses Based on Antidepressant Dispensation Records 
 
Exposure status was based on dispensation data for the timing of exposure comparisons and paternal comparisons. 
Dispensation windows used in main analyses were: (1) only before pregnancy, (2) during the first trimester of 
pregnancy, (3) only during the second and/or third trimester, and (4) only after pregnancy (see eFigure 1 for a 
diagram of the dispensation windows). We have presented the distribution of outcomes and covariates stratified by 
maternal dispensation windows for any antidepressants and for SSRIs specifically (eTables 5 and 6, respectively).  
In addition, we have presented the distribution of outcomes and covariates for offspring of fathers with first-
trimester dispensations and offspring of fathers without dispensations before, during, or after pregnancy (see eTable 
7 for any antidepressant dispensations and eTable 8 for SSRI dispensations).  
 
Timing of exposure analyses compared associations with dispensations before pregnancy to associations with first-
trimester dispensations. We evaluated whether these associations differed statistically using Wald χ2 tests. We also 
compared the fit of two models using the Akaike information criterion (AIC). The first model included four 
parameters that compared the following groups to offspring unexposed to any antidepressants: (1) dispensations 
only before pregnancy, (2) dispensations for the first trimester of pregnancy, (3) dispensations only for the second 
and/or third trimester of pregnancy, and (4) dispensations only after pregnancy. The second model constrained the 
first two parameters to be equal so that the model included the following three parameters: (1) dispensations before 
and/or during the first trimester of pregnancy, (2) dispensations for the second and/or third trimester of pregnancy, 
and (3) dispensations after pregnancy. Thus, the four-parameter model included separate parameters for 
dispensations before pregnancy and first-trimester dispensations, whereas the three-parameter model included one 
parameter for dispensations before pregnancy and first-trimester dispensations. If associations with dispensations 
before pregnancy differed from associations with dispensations during the first trimester of pregnancy, the model 
that included separate parameters for those two time periods would fit better.  
 
For preterm birth, the association between dispensations before pregnancy and preterm birth was significantly 
smaller than the association between first-trimester dispensations and preterm birth (p = 0.0007 for any 
antidepressant, p = 0.001 for SSRIs specifically), and the four-parameter model fit better than the three-parameter 
model. However, for small for gestational age, autism spectrum disorder, and attention-deficit/hyperactivity disorder 
the associations with dispensations before pregnancy did not significantly differ from associations with first-
trimester dispensations (small for gestational age: p = 0.64 for any antidepressant,  p = 0.74 for SSRIs specifically; 
autism spectrum disorder: p = 0.21 for any antidepressant,  p = 0.46 for SSRIs specifically; attention-
deficit/hyperactivity disorder: p = 0.49 for any antidepressant,  p = 0.76 for SSRIs specifically). The three-parameter 
model also fit better than the four-parameter model for these outcomes. The four-parameter model estimates and the 
model fit for both models are presented in eTable 9. 
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eTable 5. Descriptive statistics stratified by maternal dispensation windows for any antidepressants 
  
Before 
pregnancy 
dispensations 
only  
(n=8203 [1.16%]) 
1
st
-trimester 
dispensations 
(n=26477 [3.74%]) 
2
nd
 and/or 3
rd
 
trimester 
dispensations 
only 
 (n=746 [0.11%]) 
After pregnancy 
dispensations 
only  
(n=6574 [0.93%]) 
No 
dispensations 
before, during, 
or after 
pregnancy 
(n=666450) 
 
No. (%) No. (%) No. (%) No. (%) No. (%) 
Offspring outcomes      
  Preterm birth 484 (5.90) 1842 (6.96) 42 (5.63) 419 (6.37) 30945 (4.64) 
  Small for gestational age 205 (2.50) 660 (2.49) 20 (2.68) 148 (2.25) 14348 (2.15) 
  Autism spectrum disorder
a
 35 (0.96) 143 (1.14) 6 (2.00) 29 (0.90) 2044 (0.59) 
  Attention-deficit/hyperactivity disorder
a
 27 (1.03) 80 (0.83) 0 (0.00) 24 (0.88) 931 (0.34) 
 
Pregnancy covariates 
 
 
   
  First born 4097 (49.95) 12244 (46.24) 281 (37.67) 2666 (40.55) 296400 (44.47) 
  Second born 2298 (28.01) 8224 (31.06) 261 (34.99) 2586 (39.34) 250549 (37.59) 
  Third born 1219 (14.86) 4031 (15.22) 130 (17.43) 898 (13.66) 85821 912.88) 
  Fourth born or higher 589 (7.18) 1978 (7.47) 74 (9.92) 424 (6.45) 33680 (5.05) 
  Born 2006 to 2009
b
 4316 (52.61) 13570 (51.25) 364 (48.79) 3514 (53.45) 377773 (56.68) 
  Born 2010 to 2012
b
 3887 (47.39) 12907 (48.75) 382 (51.21) 3060 (46.55) 288677 (43.32) 
 
Maternal covariates 
 
 
   
  Age at birth      
      < 20 years 152 (1.85) 439 (1.66) 20 (2.68) 172 (2.62) 9470 (1.42) 
      20 to 24 years 1244 (15.17) 3345 (12.63) 134 (17.96) 1080 (16.43) 84356 (12.66) 
      25 to 29 years 2257 (27.51) 7030 (26.55) 211 (28.28) 1871 (28.46) 193442 (29.03) 
      30 to 34 years 2660 (32.43) 8710 (32.90) 203 (27.21) 2080 (31.64) 234498 (35.19) 
      35 to 39 years 1522 (18.55) 5549 (20.96) 133 (17.83) 1088 (16.55) 120041 (18.01) 
      > 40 years 368 (4.49) 1404 (5.30) 45 (6.03) 283 (4.30) 24643 (3.70) 
  Education      
     Primary and lower secondary, < 9 years 152 (1.85) 346 (1.31) 28 (3.75) 108 (1.64) 17093 (2.56) 
     Primary and lower secondary, 9 years 1077 (13.13) 3482 (13.15) 138 (18.58) 941 (14.31) 44637 (6.70) 
     Upper secondary, 1-2 years 1103 (13.45) 3513 (13.27) 97 (13.00) 820 (12.47) 61107 (9.17) 
     Upper secondary, 3 years 2363 (28.81) 7534 (28.45) 186 (24.93) 1922 (29.24) 189191 (28.39) 
     Post-secondary, < 3 years 1030 (12.56) 3358 (12.68) 104 (13.94) 789 (12.00) 84692 (12.71) 
     Post-secondary, > 3 years 2408 (29.36) 8045 (30.38) 189 (25.34) 1956 (29.75) 261200 (39.19) 
     Postgraduate  70 (0.85) 199 (0.75) 4 (0.54) 38 (0.58) 8530 (1.28) 
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Before 
pregnancy 
dispensations 
only  
(n=8203 [1.16%]) 
1
st
-trimester 
dispensations 
(n=26477 [3.74%]) 
2
nd
 and/or 3
rd
 
trimester 
dispensations 
only 
 (n=746 [0.11%]) 
After pregnancy 
dispensations 
only  
(n=6574 [0.93%]) 
No 
dispensations 
before, during, 
or after 
pregnancy 
(n=66450) 
 
No. (%) No. (%) No. (%) No. (%) No. (%) 
  Nationality (Swedish) 6839 (83.37) 23220 (87.70) 543 (72.79) 5481 (83.37) 523334 (78.53) 
  Criminal convictions (any) 1417 (17.27) 4676 (17.66) 158 (21.18) 1058 (16.09) 62678 (9.40) 
  Severe psychiatric problem
c
 336 (4.10) 1736 (6.56) 37 (4.96) 370 (5.63) 3604 (0.54) 
  Suicide attempt (definite or uncertain) 1003 (12.23) 3685 (13.92) 101 (13.54) 676 (10.28) 23861 (3.58) 
 
Paternal covariates 
 
 
   
  Age at birth      
      < 20 years 55 (0.67) 185 (0.70) 11 (1.47) 50 (0.76) 3033 (0.46) 
      20 to 24 years 708 (8.63) 2006 (7.58) 73 (9.79) 599 (9.11) 39498 (5.93) 
      25 to 29 years 1801 (21.96) 5543 (20.94) 165 (22.12) 1461 (22.22) 139335 (20.91) 
      30 to 34 years  2464 (30.04) 8096 (30.58) 200 (26.81) 2101 (31.96) 226642 (34.01) 
      35 to 39 years 1897 (23.13) 6260 (23.64) 176 (23.59) 1472 (22.39) 161388 (24.22) 
      > 40 years 1278 (15.58) 4387 (16.57) 121 (16.22) 891 (13.55) 96554 (14.49) 
  Education      
     Primary and lower secondary, < 9 years 165 (2.01) 398 (1.50) 21 (2.82) 131 (1.99) 14251 (2.14) 
     Primary and lower secondary, 9 years 1027 (12.52) 3200 (12.09) 96 (12.87) 799 (12.15) 59882 (8.99) 
     Upper secondary, 1-2 years 1569 (19.13) 5345 (20.19) 150 (20.11) 1234 (18.77) 111799 (16.78) 
     Upper secondary, 3 years 2569 (31.32) 8243 (31.13) 224 (30.03) 2189 (33.30) 200790 (30.13) 
     Post-secondary, < 3 years 1052 (12.82) 3394 (12.82) 101 (13.54) 827 (12.58) 94032 (14.11) 
     Post-secondary, > 3 years 1740 (21.21) 5536 (20.91) 143 (19.17) 1315 (20.00) 173513 (26.04) 
     Postgraduate  81 (0.99) 361 (1.36) 11 (1.47) 79 (1.20) 12183 (1.83) 
  Nationality (Swedish) 6704 (81.73) 22443 (84.76) 535 (71.72) 5415 (82.37) 522698 (78.43) 
  Criminal convictions (any) 3263 (39.78) 10434 (39.41) 309 (41.42) 2516 (38.27) 213431 (32.03) 
  Severe psychiatric problem
c
 78 (0.95) 351 (1.33) 8 (1.07) 88 (1.34) 3177 (0.48) 
  Suicide attempt (definite or uncertain) 488 (5.95) 1560 (5.89) 46 (6.17) 343 (5.22) 25464 (3.82) 
All percentages are based on the number of offspring. 
a
Age 6 Kaplan Meier estimates.
 b
Year of birth is presented in bins in eTable 5 but was not binned when used as a covariate in 
models. 
c
Severe psychiatric problem was defined as an inpatient or outpatient diagnosis of schizophrenia, bipolar disorder, or other non-drug induced psychosis. 
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eTable 6. Descriptive statistics stratified by maternal dispensation windows for SSRIs 
  
Before 
pregnancy 
dispensations 
(n=6674 [0.94%]) 
1
st
-trimester 
dispensations 
(n=22125 [3.12%]) 
2
nd
/3
rd
 trimester 
dispensations 
(n=775 [0.11%]) 
After pregnancy 
dispensations 
(n=6007 [0.85%]) 
No 
dispensations 
before, during, 
or after 
pregnancy 
(n=672869) 
 
No. (%) No. (%) No. (%) No. (%) No. (%) 
Offspring outcomes      
  Preterm birth 381 (5.71) 1512 (6.83) 41 (5.29) 378 (6.29) 31420 (4.67) 
  Small for gestational age 167 (2.50) 550 (2.49) 21 (2.71) 130 (2.16) 14513 (2.16) 
  Autism spectrum disorder
a
 30 (1.05) 115 (1.10) 6 (1.89) 31 (1.04) 2075 (0.59) 
  Attention-deficit/hyperactivity disorder
a
 21 (0.98) 64 (0.79) 1 (0.38) 24 (0.96) 952 (0.35) 
 
Pregnancy covariates 
 
  
  
  First born 3294 (49.36) 10220 (46.19) 293 (37.81) 2471 (41.14) 299410 (44.50) 
  Second born 1928 (28.89) 7022 (31.74) 274 (35.25) 2370 (39.45) 252324 (37.50) 
  Third born 997 (14.94) 3325 (15.03) 130 (16.77) 803 (13.37) 86844 (12.91) 
  Fourth born or higher 455 (6.82) 1558 (7.04) 78 (10.06) 363 (6.04) 34291 (5.10) 
  Born 2006 to 2009
b
 3550 (53.19) 11212 (50.68) 374 (48.26) 3192 (53.14) 381209 (56.65) 
  Born 2010 to 2012
b
 3124 (46.81) 10913 (49.32) 401 (51.74) 2815 (46.86) 291660 (43.35) 
 
Maternal covariates 
 
  
  
  Age at birth      
      < 20 years 141 (2.11) 387 (1.75) 20 (2.58) 153 (2.55) 9552 (1.42) 
      20 to 24 years 1021 (15.30) 2826 (12.77) 140 (18.06) 1000 (16.65) 85172 (12.66) 
      25 to 29 years 1855 (27.79) 5926 (26.78) 218 (28.13) 1694 (28.20) 195118 (29.00) 
      30 to 34 years 2158 (32.33) 7269 (32.85) 216 (27.87) 1889 (31.45) 236619 (35.17) 
      35 to 39 years 1214 (18.19) 4580 (20.70) 137 (17.68) 1019 (16.96) 121383 (18.04) 
      > 40 years 285 (4.27) 1137 (5.14) 44 (5.68) 252 (4.20) 25025 (3.72) 
  Education      
     Primary and lower secondary, < 9 years 108 (1.62) 254 (1.15) 29 (3.74) 90 (1.50) 17246 (2.56) 
     Primary and lower secondary, 9 years 880 (13.19) 2795 (12.63) 149 (19.23) 831 (13.83) 45620 (6.78) 
     Upper secondary, 1-2 years 857 (12.84) 2802 (12.66) 104 (13.42) 740 (12.32) 62137 (9.23) 
     Upper secondary, 3 years 1901 (28.48) 6303 (28.49) 194 (25.03) 1756 (29.23) 191042 (28.39) 
     Post-secondary, < 3 years 861 (12.90) 2831 (12.80) 109 (14.06) 730 (12.15) 85442 (12.70) 
     Post-secondary, > 3 years 2012 (30.15) 6973 (31.52) 185 (23.87) 1824 (30.36) 262804 (39.06) 
     Postgraduate  55 (0.82) 167 (0.75) 5 (0.65) 36 (0.60) 8578 (1.27) 
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Before 
pregnancy 
dispensations 
(n=6674 [0.94%]) 
1
st
-trimester 
dispensations 
(n=22125 [3.12%]) 
2
nd
/3
rd
 trimester 
dispensations 
(n=775 [0.11%]) 
After pregnancy 
dispensations 
(n=6007 [0.85%]) 
No 
dispensations 
before, during, 
or after 
pregnancy 
(n=672869) 
 
No. (%) No. (%) No. (%) No. (%) No. (%) 
  Nationality (Swedish) 5616 (84.15) 19486 (88.07) 570 (73.55) 5036 (83.84) 528709 (78.58) 
  Criminal convictions (any) 1160 (17.38) 3750 (16.95) 165 (21.29) 974 (16.21) 63938 (9.50) 
  Severe psychiatric problem
c
 278 (4.17) 1418 (6.41) 49 (6.32) 358 (5.96) 3980 (0.59) 
  Suicide attempt (definite or uncertain) 817 (12.24) 2927 (13.23) 112 (14.45) 625 (10.40) 24845 (3.69) 
 
Paternal covariates 
 
  
  
  Age at birth      
      < 20 years 46 (0.69) 154 (0.70) 12 (1.55) 47 (0.78) 3075 (0.46) 
      20 to 24 years 608 (9.11) 1682 (7.60) 76 (9.81) 551 (9.17) 39967 (5.94) 
      25 to 29 years 1441 (21.59) 4662 (21.07) 169 (21.81) 1341 (22.32) 140692 (20.91) 
      30 to 34 years 2054 (30.78) 6823 (30.84) 216 (27.87) 1889 (31.45) 228521 (33.96) 
      35 to 39 years 1522 (22.80) 5248 (23.72) 175 (22.58) 1353 (22.52) 162895 (24.21) 
      > 40 years 1003 (15.03) 3556 (16.07) 127 (16.39) 826 (13.75) 97719 (14.52) 
  Education      
     Primary and lower secondary, < 9 years 126 (1.89) 305 (1.38) 22 (2.84) 115 (1.91) 14398 (2.14) 
     Primary and lower secondary, 9 years 847 (12.69) 2612 (11.81) 108 (13.94) 724 (12.05) 60713 (9.02) 
     Upper secondary, 1-2 years 1241 (18.59) 4347 (19.65) 158 (20.39) 1110 (18.48) 113241 (16.83) 
     Upper secondary, 3 years 2076 (31.11) 6938 (31.36) 236 (30.45) 1996 (33.23) 202769 (30.13) 
     Post-secondary, < 3 years 864 (12.95) 2880 (13.02) 100 (12.90) 759 (12.64) 94803 (14.09) 
     Post-secondary, > 3 years 1452 (21.76) 4731 (21.38) 139 (17.94) 1227 (20.43) 174698 (25.96) 
     Postgraduate  68 (1.02) 312 (1.41) 12 (1.55) 76 (1.27) 12247 (1.82) 
  Nationality (Swedish) 5491 (82.27) 18855 (85.22) 559 (72.13) 4960 (82.57) 527930 (78.46) 
  Criminal convictions (any) 2614 (39.17) 8608 (38.91) 333 (42.97) 2285 (38.04) 216113 (32.12) 
  Severe psychiatric problem
c
 74 (1.11) 289 (1.31) 8 (1.03) 87 (1.45) 3244 (0.48) 
  Suicide attempt (definite or uncertain) 416 (6.23) 1282 (5.79) 56 (7.23) 312 (5.19) 25835 (3.84) 
All percentages are based on the number of offspring. 
a
Age 6 Kaplan Meier estimates.
 b
Year of birth is presented in bins in eTable 6 but was not binned when used as a covariate in 
models. 
c
Severe psychiatric problem was defined as an inpatient or outpatient diagnosis of schizophrenia, bipolar disorder, or other non-drug induced psychosis. 
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eTable 7. Descriptive statistics stratified by paternal first-trimester dispensations 
of any antidepressants 
  
1
st
-trimester 
dispensations 
(n=18,727) 
No dispensations before, 
during, or after pregnancy 
(n= 675,620) 
 
No. (%) No. (%) 
Offspring outcomes   
  Preterm birth 992 (5.30) 32024 (4.74) 
  Small for gestational age 423 (2.26) 14623 (2.16) 
  Autism spectrum disorder
a
 77 (0.81) 2125 (0.61) 
  Attention-deficit/hyperactivity disorder
a
 49 (0.68) 972 (0.36) 
 
Pregnancy covariates 
 
 
  First born 7893 (42.15) 301793 (44.67) 
  Second born 6554 (35.00) 252447 (37.37) 
  Third born 2833 (15.13) 87218 (12.91) 
  Fourth born or higher 1447 (7.73) 34162 (5.06) 
  Born 2006 to 2009
b
 10064 (53.74) 381620 (56.48) 
  Born 2010 to 2012
b
 8663 (46.26) 294000 (43.52) 
 
Maternal covariates 
 
 
  Age at birth   
      < 20 years 309 (1.65) 9583 (1.42) 
      20 to 24 years 2195 (11.72) 85688 (12.68) 
      25 to 29 years 4955 (26.46) 195867 (28.99) 
      30 to 34 years 6373 (34.03) 237503 (35.15) 
      35 to 39 years 3971 (21.20) 121792 (18.03) 
      > 40 years 924 (4.93) 25187 (3.73) 
  Education   
     Primary and lower secondary, < 9 years 600 (3.20) 16585 (2.45) 
     Primary and lower secondary, 9 years 1838 (9.81) 46592 (6.90) 
     Upper secondary, 1-2 years 2140 (11.43) 62703 (9.28) 
     Upper secondary, 3 years 5271 (28.15) 191879 (28.40) 
     Post-secondary, < 3 years 2305 (12.31) 85920 (12.72) 
     Post-secondary, > 3 years 6374 (34.04) 263433 (38.99) 
     Postgraduate  199 (1.06) 8508 (1.26) 
  Nationality (Swedish) 14604 (77.98) 534445 (79.10) 
  Criminal convictions (any) 2586 (13.81) 65127 (9.64) 
  Severe psychiatric problem
c
 379 (2.02) 5393 (0.80) 
  Suicide attempt (definite or uncertain) 1192 (6.37) 27118 (4.01) 
 
Paternal covariates 
 
 
  Age at birth   
      < 20 years 83 (0.44) 3158 (0.47) 
      20 to 24 years 844 (4.51) 40960 (6.06) 
      25 to 29 years 3099 (16.55) 142359 (21.07) 
      30 to 34 years 5746 (30.68) 229720 (34.00) 
      35 to 39 years 4980 (26.59) 162975 (24.12) 
      > 40 years 3975 (21.23) 96448 (14.28) 
  Education   
     Primary and lower secondary, < 9 years 474 (2.53) 13993 (2.07) 
     Primary and lower secondary, 9 years 2640 (14.10) 59944 (8.87) 
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1
st
-trimester 
dispensations 
(n=18,727) 
No dispensations before, 
during, or after pregnancy 
(n= 675,620) 
 No. (%) No. (%) 
     Upper secondary, 1-2 years 3871 (20.67) 113159 (16.75) 
     Upper secondary, 3 years 4931 (26.33) 205399 (30.40) 
     Post-secondary, < 3 years 2347 (12.53) 95382 (14.12) 
     Post-secondary, > 3 years 4156 (22.19) 175515 (25.98) 
     Postgraduate  308 (1.64) 12228 (1.81) 
  Nationality (Swedish) 14870 (79.40) 532719 (78.85) 
  Criminal convictions (any) 8514 (45.46) 214354 (31.73) 
  Severe psychiatric problem
c
 978 (5.22) 2142 (0.32) 
  Suicide attempt (definite or uncertain) 1808 (9.65) 24632 (3.65) 
All percentages are based on the number of offspring. 
a
Age 6 Kaplan Meier estimates.
 b
Year of birth is presented in bins in eTable 7 
but was not binned when used as a covariate in models. 
c
Severe psychiatric problem was defined as an inpatient or outpatient 
diagnosis of schizophrenia, bipolar disorder, or other non-drug induced psychosis. 
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eTable 8. Descriptive statistics stratified by paternal first-trimester dispensations 
of SSRIs 
  
1
st
-trimester 
dispensations 
(n=13,521) 
No dispensations before, 
during, or after pregnancy 
(n=684,714 ) 
 
No. (%) No. (%) 
Offspring outcomes   
  Preterm birth 720 (5.33) 32486 (4.74) 
  Small for gestational age 291 (2.15) 14851 (2.17) 
  Autism spectrum disorder
a
 55 (0.75) 2157 (0.61) 
  Attention-deficit/hyperactivity disorder
a
 37 (0.67) 994 (0.36) 
 
Pregnancy covariates 
 
 
  First born 5754 (42.56) 305525 (44.62) 
  Second born 4776 (35.32) 255557 (37.32) 
  Third born 2032 (15.03) 88602 (12.94) 
  Fourth born or higher 959 (7.09) 35030 (5.12) 
  Born 2006 to 2009
b
 7252 (53.64) 386666 (56.47) 
  Born 2010 to 2012
b
 6269 (46.36) 298048 (43.53) 
 
Maternal covariates 
 
 
  Age at birth   
      < 20 years 222 (1.64) 9756 (1.42) 
      20 to 24 years 1496 (11.06) 87065 (12.72) 
      25 to 29 years 3616 (26.74) 198353 (28.97) 
      30 to 34 years 4675 (34.58) 240266 (35.09) 
      35 to 39 years 2859 (21.14) 123621 (18.05) 
      > 40 years 653 (4.83) 25653 (3.75) 
  Education   
     Primary and lower secondary, < 9 years 347 (2.57) 17032 (2.49) 
     Primary and lower secondary, 9 years 1216 (8.99) 47800 (6.98) 
     Upper secondary, 1-2 years 1471 (10.88) 63936 (9.34) 
     Upper secondary, 3 years 3816 (28.22) 194470 (28.40) 
     Post-secondary, < 3 years 1656 (12.25) 86992 (12.70) 
     Post-secondary, > 3 years 4873 (36.04) 265887 (38.83) 
     Postgraduate  142 (1.05) 8597 (1.26) 
  Nationality (Swedish) 10890 (80.54) 540855 (78.99) 
  Criminal convictions (any) 1756 (12.99) 66667 (9.74) 
  Severe psychiatric problem
c
 248 (1.83) 5608 (0.82) 
  Suicide attempt (definite or uncertain) 839 (6.21) 27761 (4.05) 
 
Paternal covariates 
 
 
  Age at birth   
      < 20 years 67 (0.50) 3201 (0.47) 
      20 to 24 years 608 (4.50) 41491 (6.06) 
      25 to 29 years 2300 (17.01) 143887 (21.01) 
      30 to 34 years 4284 (31.68) 232237 (33.92) 
      35 to 39 years 3649 (26.99) 165167 (24.12) 
      > 40 years 2613 (19.33) 98731 (14.42) 
  Education   
     Primary and lower secondary, < 9 years 270 (2.00) 14374 (2.10) 
     Primary and lower secondary, 9 years 1764 (13.05) 61624 (9.00) 
     Upper secondary, 1-2 years 2705 (20.01) 115293 (16.84) 
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1
st
-trimester 
dispensations 
(n=13,521) 
No dispensations before, 
during, or after pregnancy 
(n=684,714 ) 
 No. (%) No. (%) 
     Upper secondary, 3 years 3658 (27.05) 207594 (30.32) 
     Post-secondary, < 3 years 1692 (12.51) 96471 (14.09) 
     Post-secondary, > 3 years 3199 (23.66) 177024 (25.85) 
     Postgraduate  233 (1.72) 12334 (1.80) 
  Nationality (Swedish) 11062 (81.81) 539150 (78.74) 
  Criminal convictions (any) 5885 (43.52) 219182 (32.01) 
  Severe psychiatric problem
c
 620 (4.59) 2634 (0.38) 
  Suicide attempt (definite or uncertain) 1126 (8.33) 25773 (3.76) 
All percentages are based on the number of offspring. 
a
Age 6 Kaplan Meier estimates.
 b
Year of birth is presented in bins in eTable 8 
but was not binned when used as a covariate in models. 
c
Severe psychiatric problem was defined as an inpatient or outpatient 
diagnosis of schizophrenia, bipolar disorder, or other non-drug induced psychosis. 
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eTable 9. Adjusted associations between maternal antidepressant dispensations before pregnancy, during the 
first trimester of pregnancy, during the second and/or third trimester of pregnancy, and after pregnancy and 
offspring birth and neurodevelopmental outcomes 
 
Four parameter model estimates Model fit 
 
1. Before 
pregnancy 
2. 1
st
 trimester 
3. 2
nd
 and/or 3
rd
 
trimester 
4. After 
pregnancy 
Four 
Parameter 
model  
Parameters 
1 and 2 
constrained 
to equality  
Any antidepressant   
 OR 95% CI OR 95% CI OR 95% CI OR 95% CI AIC AIC 
Preterm birth 1.17 1.07-1.28 1.40 1.33-1.47 1.15 0.84-1.57 1.34 1.21-1.48 268512.64 268522.38 
Small for gestational age 1.07 0.93-1.24 1.12 1.03-1.21 1.17 0.75-1.84 1.05 0.89-1.24 143724.04 143722.26 
 
          
 HR 95% CI HR 95% CI HR 95% CI HR 95% CI AIC AIC 
Autism spectrum disorder 1.40 1.02-1.93 1.75 1.49-2.07 2.18 0.98-4.85 1.45 1.03-2.04 65876.69 65876.32 
Attention deficit/hyperactivity disorder 2.09 1.53-2.86 1.85 1.55-2.20 0.24 0.06-1.01 1.86 1.39-2.48 46856.51 46854.97 
SSRIs   
  
   
 
  
 OR 95% CI OR 95% CI OR 95% CI OR 95% CI AIC AIC 
Preterm birth 1.13 1.02-1.25 1.37 1.30-1.45 1.06 0.77-1.45 1.31 1.18-1.46 268561.62 268570.72 
Small for gestational age 1.09 0.94-1.28 1.13 1.03-1.23 1.17 0.76-1.82 1.01 0.85-1.21 143723.97 143722.08 
           
 HR 95% CI HR 95% CI HR 95% CI HR 95% CI AIC AIC 
Autism spectrum disorder 1.49 1.06-2.10 1.72 1.43-2.06 2.13 0.96-4.76 1.64 1.17-2.29 65881.61 65880.16 
Attention deficit/hyperactivity disorder 1.93 1.35-2.74 1.81 1.50-2.19 0.50 0.17-1.42 1.86 1.37-2.52 46876.16 46874.25 
OR = odds ratio. HR = hazard ratio. CI = confidence interval. Models were fit in a sample of 708,450 offspring. The four parameter model included the following four parameters that 
compared the following groups to offspring unexposed to any antidepressants: (1) dispensations only before pregnancy, (2) dispensations for the first trimester of pregnancy, (3) 
dispensations only for the second and/or third trimester of pregnancy, and (4) dispensations only after pregnancy. Models also controlled for parity and year of birth and maternal and 
paternal country of birth, age at childbearing, highest level of completed education, history of any criminal convictions, history of severe psychiatric problems, and history of any suicide 
attempts. Models were compared using the Akaike information criterion (AIC). 
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Time 
point 
Conception 
 – 270 days 
Conception 
 – 180 days 
Conception 
 – 90 days 
Conception 
Conception 
 + 90 days 
Conception 
 + 180 days 
Birth 
Birth 
 + 90 days 
Birth 
 + 180 days 
Window 
                  
 Before pregnancy only              
     1
st
 trimester          
         2
nd
 and/or 3
rd
 trimester only      
             After pregnancy only  
 
Figure legend:        
  At least one dispensation occurred during this period 
  No dispensations occurred during this period 
 
eFigure 1. Dispensation windows.  The before-pregnancy-only window included offspring of women who were dispensed antidepressants in the period 270 days before conception 
to 90 days before conception but were not dispensed antidepressants in the period 90 days before conception to 180 days after birth. The 1st-trimester window included offspring of 
women who were dispensed antidepressants in the period 90 days before conception to 90 days after conception. Offspring of women who were also dispensed antidepressants 
before or after the defined exposure window were considered exposed in the 1
st
-trimester window. The 2
nd
- and/or 3
rd
-trimester only window included offspring of women who were 
dispensed antidepressants in the period 90 days after conception to birth but were not dispensed antidepressants in the period 270 days before conception to 90 days after conception 
and were not dispensed antidepressants in the period 180 days after birth. The after pregnancy only window included offspring of women who were dispensed antidepressants in the 
period 180 days after birth but were not dispensed antidepressants in the period 270 days before conception through birth.  
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eSupplement C:  
Test of Exposure Misclassification 
 
In the sample of 708,450 offspring born between 2006 and 2012, maternal self-report data on antidepressant use was 
used in combination with maternal antidepressant dispensation data to evaluate whether exposure misclassification 
may have biased the results.  
 
The main analyses used two different definitions for first-trimester antidepressant exposure. First-trimester exposure 
was defined (a) according to maternal self-reports and (b) according to dispensation data. Women self-reported 
antidepressant use at the first antenatal visit, which typically occur between the 10
th
 and 12
th
 week of pregnancy. 
First-trimester exposure based on dispensation records was defined as having at least one dispensation between 90 
days before estimated conception and 90 days after estimated conception. (eFigure 1 shows a diagram of exposure 
windows.)  
 
To test for biases from exposure misclassification, we first calculated kappa estimates to assess agreement between 
the two exposures definitions used in the main analyses.  
 
Then, four additional exposure definitions were created. 
 
The first definition classified cases as exposed if either exposure definition used in the main analyses indicated 
exposure. According to this definition, 28,158 (4.0% of the 2006-2012 cohort) offspring were exposed to any 
antidepressant, and 23,422 (3.3%) offspring were exposed to SSRIs specifically.  
 
The second definition classified cases as exposed if both exposure definitions used in the main analyses indicated 
exposure. According to this definition, 13,435 (1.9%) offspring were exposed to any antidepressant, and 11,516 
(1.6%) offspring were exposed to SSRIs specifically.   
 
The third definition used a narrower window than the main analyses’ first-trimester dispensation definition. 
Specifically, it defined exposure as having at least one dispensation between 30 days before estimated conception 
and 90 days after estimated conception. According to this definition, 7,455 (1.1%) offspring were exposed to any 
antidepressant, and 5,593 (0.8%) offspring were exposed to SSRIs specifically.  
 
The fourth definition required at least two dispensations in the dispensation window used in the main analyses 
(between 90 days before estimated conception and 90 days after estimated conception).  According to this definition, 
14,288 (2.0%) offspring were exposed to any antidepressant, and 11,333 (1.6%) offspring were exposed to SSRIs 
specifically. 
 
Models assessing associations between the four additional definitions of exposure and offspring problems included 
pregnancy-related, maternal, and paternal covariates.  
 
In general, the results from the sensitivity analyses suggest that exposure misclassification and self-report biases did 
not influence the results.  
 
Maternal reports and dispensation records showed substantial agreement (kappa = 0.64, 95% CI [0.63 to 0.64] for 
any antidepressant, and kappa = 0.65, 95% CI [0.65 to 0 .66] for SSRIs). Additionally, commensurate associations 
were found across the two exposure definitions used in the main paper and the four additional definitions described 
here (Table 2, Table 3, eTable 10).  
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eTable 10. Adjusted associations between four definitions of first-trimester antidepressant use and offspring 
birth and neurodevelopmental outcomes 
 
Exposure according  
to self-reported use OR  
dispensation data 
Exposure according  
to self-report use AND  
dispensation data 
Narrower first-trimester 
exposure dispensation 
window 
Two dispensations 
during 1
st
 trimester 
Any antidepressant 
 OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
Preterm birth 1.38 1.31-1.45 1.40 1.31-1.50 1.44 1.36-1.52 1.54 1.41-1.68 
Small for gestational age 1.12 1.03-1.21 1.13 1.01-1.26 1.14 1.04-1.25 1.13 0.98-1.31 
 
        
 HR 95% CI HR 95% CI HR 95% CI HR 95% CI 
Autism spectrum disorder 1.71 1.46-2.01 1.83 1.46-2.28 1.85 1.54-2.22 1.72 1.28-2.31 
Attention deficit/hyperactivity disorder 1.70 1.44-2.00 1.75 1.38-2.22 1.83 1.50-2.22 1.81 1.34-2.44 
SSRIs         
 OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
Preterm birth 1.34 1.27-1.42 1.34 1.24-1.44 1.42 1.34-1.51 1.45 1.31-1.61 
Small for gestational age 1.12 1.03-1.22 1.13 1.01-1.28 1.17 1.06-1.29 1.17 0.99-1.38 
         
 HR 95% CI HR 95% CI HR 95% CI HR 95% CI 
Autism spectrum disorder 1.71 1.44-2.04 1.75 1.37-2.24 1.83 1.50-2.24 1.71 1.21-2.41 
Attention deficit/hyperactivity disorder 1.62 1.35-1.95 1.76 1.36-2.28 1.87 1.51-2.31 1.83 1.29-2.58 
OR = odds ratio. HR = hazard ratio. CI = confidence interval. Models were fit in a sample of 708,450 offspring. Models controlled for parity and year of birth and maternal and paternal 
country of birth, age at childbearing, highest level of completed education, history of any criminal convictions, history of severe psychiatric problems, and history of any suicide 
attempts. 
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eSupplement D: 
Test of Generalizability of Sibling Comparisons 
 
An assumption of sibling comparisons is that results will generalize to other samples (e.g., families with only one 
child, families without variability in the outcome). An additional analysis was conducted to test this assumption. 
Specifically, given that families with single included offspring were excluded from sibling comparison analyses 
(because they cannot provide information), we assessed baseline and adjusted associations in a subsample of 
1,139,753 offspring who had at least one sibling in the dataset in order to assess the generalizability of the sibling 
comparison results. Although associations with small for gestational age were not statistically significant, the 
general pattern of results were consistent with findings from the main analyses (eTable 11), suggesting that 
reduction in the effect sizes in the sibling-comparison models, particularly for the neurodevelopmental outcomes, 
was not due to the exclusion of single-offspring families. 
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eTable 11. Baseline and adjusted associations between maternal self-reported 
first-trimester antidepressant use and offspring birth and neurodevelopmental 
outcomes in multiple-offspring families 
 
Baseline Model Adjusted Model 
Any antidepressant   
 OR 95% CI OR 95% CI 
Preterm birth 1.48 1.38-1.58 1.37 1.28-1.47 
Small for gestational age 1.06 0.94-1.20 1.06 0.94-1.19 
 
    
 HR 95% CI HR 95% CI 
Autism spectrum disorder 2.08 1.80-2.39 1.70 1.47-1.96 
Attention deficit/hyperactivity disorder 2.09 1.89-2.31 1.48 1.34-1.64 
SSRIs     
 OR 95% CI OR 95% CI 
Preterm birth 1.39 1.29-1.50 1.29 1.20-1.39 
Small for gestational age 1.03 0.90-1.18 1.03 0.90-1.18 
     
 HR 95% CI HR 95% CI 
Autism spectrum disorder 2.06 1.75-2.42 1.69 1.44-1.99 
Attention deficit/hyperactivity disorder 2.18 1.94-2.44 1.54 1.37-1.73 
OR = odds ratio. HR = hazard ratio. CI = confidence interval. All models were fit in a sample of 1,139,753 offspring who had at least 
one sibling in the dataset. Baseline models controlled for parity and year of birth. Adjusted models controlled for parity and year of 
birth and maternal and paternal country of birth, age at childbearing, highest level of completed education, history of any criminal 
convictions, history of severe psychiatric problems, and history of any suicide attempts.  
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eSupplement E:  
Test of Confounding from Exposure to Other Psychotropic Medications 
 
Offspring with maternal self-reported first-trimester exposure to other psychotropic medications, defined as 
antiepileptic medications, antipsychotic medications, medications used to treat addictive disorders, anxiolytics, 
attention-deficit/hyperactivity disorder medication, and opioid analgesics, were identified (eTable 12 lists specific 
drug names and Anatomical Therapeutic Chemical Classification [ATC] codes). Given that 9.8% (2,204) of 
offspring exposed to antidepressants were also exposed to other psychotropic medications, associations between 
maternal self-reported first-trimester antidepressant use and offspring outcomes were assessed in a subsample of 
1,563,250 offspring who were not exposed to the other psychotropic medications. These associations were 
commensurate to associations observed in the main analyses (eTable 13), suggesting that exposure to other 
psychotropic medications did not bias the results.  
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 eTable 12. Drug names and Anatomical Therapeutic Chemical Classification 
codes for other psychotropic medications  
ATC code Medication name 
Antiepileptic medications 
N03AA01 methylphenobarbital  
N03AA02 phenobarbital  
N03AA03 primidone  
N03AA04 barbexaclone  
N03AA30 metharbital  
N03AB01 ethotoin  
N03AB02 phenytoin  
N03AB03 amino(diphenylhydantoin) valeric acid  
N03AB04 mephenytoin  
N03AB05 fosphenytoin  
N03AB52 phenytoin, combinations  
N03AB54 mephenytoin, combinations  
N03AC01 paramethadione  
N03AC02 trimethadione  
N03AC03  ethadione 
N03AD01 ethosuximide  
N03AD02 phensuximide  
N03AD03 mesuximide  
N03AD51 ethosuximide, combinations  
N03AF01 carbamazepine  
N03AF02 oxcarbazepine  
N03AF03 rufinamide  
N03AF04 eslicarbazepine  
N03AG01 valproic acid  
N03AG02 valpromide  
N03AG03 aminobutyric acid  
N03AG04 vigabatrin  
N03AG05 progabide  
N03AG06 tiagabine  
N03AX03 sultiame  
N03AX07 phenacemide  
N03AX09 lamotrigine  
N03AX10 felbamate  
N03AX11 topiramate  
N03AX12 gabapentin  
N03AX13 pheneturide  
N03AX14 levetiracetam  
N03AX15 zonisamide  
N03AX16 pregabalin  
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ATC code Medication name 
Antiepileptic medications 
N03AX17 stiripentol  
N03AX18 lacosamide  
N03AX19 carisbamate  
N03AX21 retigabine  
N03AX22 perampanel  
N03AX30 beclamide  
N05AN01 lithium  
Antipsychotic medications 
N05AA01 chlorpromazine 
N05AA02 levomepromazine 
N05AA03 promazine 
N05AA04 acepromazine  
N05AA05 triflupromazine 
N05AA06 cyamemazine  
N05AA07 chlorproethazine  
N05AB01 dixyrazine  
N05AB02 fluphenazine  
N05AB03 perphenazine  
N05AB04 prochlorperazine  
N05AB05 thiopropazate  
N05AB06 trifluoperazine  
N05AB07 acetophenazine  
N05AB08 thioproperazine  
N05AB09 butaperazine  
N05AB10 perazine  
N05AC01 periciazine  
N05AC02 thioridazine  
N05AC03 mesoridazine  
N05AD01 haloperidol 
N05AD02 trifluperidol  
N05AD03 melperone  
N05AD04 moperone  
N05AD05 pipamperone  
N05AD06 bromperidol  
N05AD07 benperidol  
N05AD08 droperidol  
N05AD09 fluanisone  
N05AE01 oxypertine  
N05AE02 molindone  
N05AE03 sertindole  
N05AE04 ziprasidone  
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ATC code Medication name 
Antipsychotic medications 
N05AE05 lurasidone  
N05AF01 flupentixol  
N05AF02 clopenthixol  
N05AF03 chlorprothixene  
N05AF04 tiotixene  
N05AF05 zuclopenthixol  
N05AG01 fluspirilene  
N05AG02 pimozide  
N05AG03 penfluridol  
N05AH01 loxapine  
N05AH02 clozapine  
N05AH03 olanzapine  
N05AH04 quetiapine  
N05AH05 asenapine  
N05AH06 clotiapine  
N05AL01 sulpiride  
N05AL02 sultopride  
N05AL03 tiapride  
N05AL04 remoxipride  
N05AL05 amisulpride  
N05AL06 veralipride  
N05AL07 levosulpiride  
N05AX07 prothipendyl  
N05AX08 risperidone  
N05AX10 mosapramine  
N05AX11 zotepine  
N05AX12 aripiprazole  
N05AX13 paliperidone  
N05AX14 iloperidone  
Medications for addictive disorders 
N07BA01  nicotine 
N07BA03 varenicline  
N07BB01  disulfiram  
N07BB02 calcium carbimide  
N07BB03 acamprosate  
N07BB04 naltrexone 
N07BC01  buprenorphine  
N07BC02 methadone  
N07BC03 levacetylmethadol  
N07BC04 lofexidine  
N07BC05 levomethadone  
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ATC code Medication name 
Medications for addictive disorders 
N07BC06 diamorphine  
N07BC51 buprenorphine, combinations  
Anxiolytics 
N03AE01  clonazepam 
N05BA01 diazepam 
N05BA02 chlordiazepoxide 
N05BA04 oxazepam 
N05BA05 clorazepate 
N05BA06 lorazepam 
N05BA12 alprazolam 
N05CD01 flurazepam 
N05CD04 estazolam 
N05CD05 triazolam 
N05CD07 temazepam 
N05CD08 midazolam 
N05CD1l0 quazepam 
N05BE01  buspirone 
N05BB01 atarax 
N05BB01 vistaril 
Attention-deficit/hyperactivity disorder medications 
 N06BA01 amfetamine 
N06BA02 dexamfetamine 
N06BA04 methylphenidate 
N06BA09 atomoxetine 
Opioids 
N02AA01 Morphine 
N02AA03 Hydromorphine 
N02AA05 Oxycodone 
N02AA55 Oxycodone/nalaxone 
N02AA59 Codeine excl. psychotropics 
N02AB01 Ketobemidone 
N02AB02 Pethidine 
N02AB03 Fentanyl 
N02AC04 Dextropropoxyphene 
N02AC54 Dextropropoxyphene excl psycholeptics 
N02AD01 Pentazocine 
N02AE01 Buprenorphine 
N02AG01 Morphine & antispasmodics 
N02AG02 Ketobemidone/ dimethylaminophenylbutene 
N02AG04 Hydromorphone & antispasmodics 
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ATC code Medication name 
Opioids 
 N02AX02 Tramadol 
ATC = Anatomical Therapeutic Chemical Classification 
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eTable 13. Baseline, adjusted, and sibling comparison associations between maternal self-reported first-trimester 
antidepressant use and offspring birth and neurodevelopmental outcomes in a subsample of offspring not 
exposed to other psychotropic medications 
 
Baseline Model Adjusted Model 
Sibling 
Comparison 
Any antidepressant 
 OR 95% CI OR 95% CI OR 95% CI 
Preterm birth 1.40 1.32-1.48 1.30 1.22-1.37 1.30 1.13-1.49 
Small for gestational age 1.12 1.03-1.23 1.11 1.02-1.22 0.92 0.73-1.17 
 
      
 HR 95% CI HR 95% CI HR 95% CI 
Autism spectrum disorder 1.85 1.64-2.10 1.53 1.35-1.74 0.67 0.48-0.94 
Attention deficit/hyperactivity disorder 2.16 1.99-2.35 1.58 1.46-1.72 1.02 0.79-1.30 
SSRIs 
 OR 95% CI OR 95% CI OR 95% CI 
Preterm birth 1.31 1.23-1.40 1.22 1.15-1.30 1.27 1.10-1.48 
Small for gestational age 1.08 0.98-1.20 1.08 0.98-1.20 0.82 0.63-1.06 
 
      
 HR 95% CI HR 95% CI HR 95% CI 
Autism spectrum disorder 1.85 1.61-2.13 1.53 1.33-1.76 0.67 0.46-0.97 
Attention deficit/hyperactivity disorder 2.17 1.98-2.39 1.58 1.44-1.74 0.96 0.73-1.27 
OR = odds ratio. HR = hazard ratio. CI = confidence interval. Baseline and adjusted models were fit in a sample of 1,563,250 offspring. Baseline models controlled for parity and year 
of birth. Adjusted models controlled for parity and year of birth and maternal and paternal country of birth, age at childbearing, highest level of completed education, history of any 
criminal convictions, history of severe psychiatric problems, and history of any suicide attempts. Sibling comparisons controlled for parity and year of birth, paternal country of birth, age 
at childbearing, highest level of completed education, history of any criminal convictions, history of severe psychiatric problems, and history of any suicide attempts, and maternal age 
at childbearing. 
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eSupplement F:  
Test of Bias from Left Censoring 
 
Given that, prior to 2001, outpatient psychiatric diagnoses were not included in the National Patient Register, we 
conducted analyses in a sample of 1,162,873 offspring born in 2001 or later to assess whether left censoring of the 
neurodevelopmental outcomes may have biased the results. The analyses also enabled us to examine whether cohort 
effects influenced the results. These analyses assessed associations between maternal self-reported first-trimester 
antidepressant use and offspring autism spectrum disorder and attention-deficit/hyperactivity disorder in baseline, 
adjusted, and sibling comparison models. The results were commensurate to the main analyses (eTable 14), 
suggesting that left censoring of the outcomes and cohort effects did not influence the results. 
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eTable 14. Baseline, adjusted, and sibling comparison associations between maternal self-reported first-trimester 
antidepressant use and offspring neurodevelopmental outcomes in a subsample born in 2001 or after 
 
Baseline Model Adjusted Model Sibling Comparison 
 
HR 95% CI HR 95% CI HR 95% CI 
Any antidepressant 
Autism spectrum disorder 2.04 1.79-2.32 1.71 1.49-1.95 0.88 0.59-1.33 
Attention-deficit/hyperactivity disorder 2.29 2.09-2.52 1.63 1.48-1.80 1.05 0.73-1.50 
SSRIs 
Autism spectrum disorder 2.06 1.78-2.38 1.75 1.51-2.02 0.90 0.58-1.40 
Attention-deficit/hyperactivity disorder 2.28 2.05-2.53 1.63 1.46-1.81 0.92 0.62-1.35 
HR = hazard ratio. CI = confidence interval. Baseline and adjusted models were fit in a sample of 1,162,873 offspring. Baseline models controlled for parity and year of birth. Adjusted 
models controlled for parity and year of birth and maternal and paternal country of birth, age at childbearing, highest level of completed education, history of any criminal convictions, 
history of severe psychiatric problems, and history of any suicide attempts. Sibling comparisons controlled for parity and year of birth, paternal country of birth, age at childbearing, 
highest level of completed education, history of any criminal convictions, history of severe psychiatric problems, and history of any suicide attempts, and maternal age at childbearing. 
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eSupplement G:  
Test of Validity of Early Autism Spectrum Disorder and Attention-Deficit/Hyperactivity 
Disorder Diagnoses 
 
There is uncertainty about the stability over time of early neurodevelopmental disorder diagnoses.
e.g.,1
 Thus, we 
conducted a sensitivity analyses to test the validity of early autism spectrum disorder and attention-
deficit/hyperactivity disorder diagnoses. Offspring diagnosed before the age of 2 were excluded from the sample and 
baseline, adjusted, and sibling comparison associations were re-examined. Associations with autism spectrum 
disorder were assessed in a sample of 1,580,430 offspring. Associations with attention-deficit/hyperactivity disorder 
were assessed in a sample of 1,580,509 offspring. Associations were commensurate to main analyses associations 
(eTable 15), suggesting that early neurodevelopmental diagnoses of potentially questionable validity did not bias the 
results.  
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eTable 15. Baseline, adjusted, and sibling comparison associations between maternal self-reported first-trimester 
antidepressant use and offspring neurodevelopmental outcomes in a sample excluding offspring diagnosed 
before age 2 years 
 
Baseline Model Adjusted Model Sibling Comparison 
 
HR 95% CI HR 95% CI HR 95% CI 
Any antidepressant 
Autism spectrum disorder 2.01 1.80-2.26 1.63 1.45-1.83 0.83 0.61-1.13 
Attention-deficit/hyperactivity disorder 2.21 2.04-2.38 1.58 1.46-1.71 1.00 0.79-1.26 
SSRIs 
Autism spectrum disorder 2.03 1.79-2.31 1.65 1.45-1.88 0.81 0.57-1.14 
Attention-deficit/hyperactivity disorder 2.25 2.06-2.46 1.60 1.46-1.75 0.95 0.73-1.23 
HR = hazard ratio. CI = confidence interval. Baseline and adjusted associations with autism spectrum disorder were assessed in a sample of 1,580,430 offspring.  Baseline and 
adjusted associations with attention-deficit/hyperactivity disorder were assessed in a sample of 1,580,509 offspring. Adjusted models controlled for parity and year of birth and 
maternal and paternal country of birth, age at childbearing, highest level of completed education, history of any criminal convictions, history of severe psychiatric problems, and history 
of any suicide attempts. Sibling comparisons controlled for parity and year of birth, paternal country of birth, age at childbearing, highest level of completed education, history of any 
criminal convictions, history of severe psychiatric problems, and history of any suicide attempts, and maternal age at childbearing. 
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eSupplement H: 
Examining Associations Between Dispensations During Later Pregnancy and Offspring 
Outcomes Among Those with a First-trimester Dispensation 
 
Given that the main analyses focused on first-trimester antidepressant exposure, we conducted a sensitivity analysis 
to explore whether continued dispensations in the second and/or third trimester was associated with the birth and 
neurodevelopmental outcomes compared to dispensations only during the first trimester. We defined a group of 
offspring, labeled Continuers, as those whose mothers had a first-trimester dispensation and a second- or third-
trimester dispensation. We defined a second group, labeled Discontinuers, as offspring whose mothers had a first-
trimester dispensation but not a second- or third-trimester dispensation. Of the 26,477 offspring in the cohort with 
first-trimester dispensations, 12,291 (46%) were Continuers and 14186 (54%) were Discontinuers. Of the 22,125 
offspring with first-trimester dispensations of SSRI specifically, 10,757 (49%) were continuers and 11,368 (51%) 
were discontinuers.  
 
We examined adjusted associations between continuation of use late in pregnancy and the birth and 
neurodevelopmental outcomes (eTable 16). The association between continued dispensations of antidepressants and 
preterm birth (OR = 1.4, 95% CI [1.3, 1.6]) and small for gestational age (OR = 1.2, 95% CI [1.0, 1.4] were 
statistically significant. The association with autism spectrum disorder was moderate in magnitude (HR = 1.3, 95% 
CI [1.0, 1.8]), though not statistically significant. Continuation of dispensations was associated with a moderate 
decrease in the risk for attention-deficit/hyperactivity disorder (HR = 0.8, 95% CI [0.5, 1.1]), but the association was 
not statistically significant.  
 
These analyses cannot differentiate whether the associations were due to increased severity of depression (i.e., 
confounding by indication severity) or the intrauterine exposure to antidepressants later in pregnancy.  
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eTable 16. Adjusted associations between continuation of antidepressant 
dispensations late in pregnancy and offspring birth and neurodevelopmental 
outcomes among those with a first-trimester dispensation 
 
Adjusted Model 
Any antidepressant 
 OR 95% CI 
Preterm birth 1.44 1.30-1.59 
Small for gestational age 1.18 1.01-1.39 
 
  
 HR 95% CI 
Autism spectrum disorder 1.32 0.96-1.81 
Attention deficit/hyperactivity disorder 0.76 0.53-1.08 
SSRIs 
 OR 95% CI 
Preterm birth 1.39 1.24-1.54 
Small for gestational age 1.21 1.01-1.44 
   
 HR 95% CI 
Autism spectrum disorder 1.22 0.86-1.74 
Attention deficit/hyperactivity disorder 0.71 0.47-1.06 
OR = odds ratio. HR = hazard ratio. CI = confidence interval. Models predicting outcomes from any antidepressant dispensation 
were fit in a sample of 26,477 offspring. Models predicting outcomes from SSRIs dispensation were fit in a sample of 22,125 
offspring. Models controlled for parity and year of birth and maternal and paternal country of birth, age at childbearing, highest level 
of completed education, history of any criminal convictions, history of severe psychiatric problems, and history of any suicide 
attempts. 
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